



US 20120064115A1

(19) United States

(12) Patent Application Publication

John et al.

(10) Pub. No.: US 2012/0064115 A1

(43) Pub. Date: Mar. 15, 2012

(54) RECOMBINANT VIRUS-LIKE PARTICLES
ENCODED BY MULTI-GENE VECTOR

C07K 14/025

(2006.01)

A61P 31/20

(2006.01)

C12N 5/10

(2006.01)

C12N 1/19

(2006.01)

A61K 39/12

(2006.01)

A61P 37/04

(2006.01)

A61P 31/12

(2006.01)

A61P 31/16

(2006.01)

C07K 14/005

(2006.01)

C07K 14/46

(2006.01)

(76) Inventors: Corinne John, Horgen (CH); Christian Schaub, Wadenswil (CH); Sabine Wellnitz, Urdorf (CH)

(21) Appl. No.: 13/318,221

(22) PCT Filed: Apr. 30, 2010

(86) PCT No.: PCT/EP2010/055943

§ 371 (c)(1),
(2), (4) Date: Oct. 31, 2011

(30) Foreign Application Priority Data

May 1, 2009 (EP) 09159287.3

Publication Classification

(51) Int. Cl.

A61K 39/295 (2006.01)
C12N 15/00 (2006.01)
C12N 1/21 (2006.01)
C07K 14/11 (2006.01)(52) U.S. Cl. 424/202.1; 530/350; 435/320.1;
435/252.33; 435/348; 435/366; 435/367;
435/369; 435/370; 435/352; 435/358; 435/325;
435/254.23; 435/254.21; 435/254.22; 424/204.1


(57) ABSTRACT

The invention describes novel virus-like particles for use as vaccines, diagnostic tools and R&D tools based on recombinant DNA and cell cultivation techniques for production. The recombinant virus-like particles of the invention are assembled by polypeptide chains that incorporate several, in particular two or more, different epitopes which are selected either (a) from different viral strains of the same virus and/or (b) from different serotypes of the same virus and/or (c) from different viral strains specific for different hosts. These epitopes are then displayed on the particle surface.


A)




B)



C)



D)



E)






Fig. 1


A)




B)



C)



D)



E)



Fig. 2




Fig. 3




A**B****C**

Fig. 4




Fig. 5




Fig. 6








Fig. 7**A****B**

Fig. 8





RECOMBINANT VIRUS-LIKE PARTICLES ENCODED BY MULTI-GENE VECTOR

FIELD OF THE INVENTION

[0001] The invention relates to recombinant virus-like particles comprising epitopes from different virus strains, and vectors encoding these.

BACKGROUND OF THE INVENTION

[0002] There is an increasing interest in small natural biomolecules using them in different aspects in biomedicine, nanotechnology and material science. Virus simulators, virus capsids or virus-like particles are very attractive because of their regular structure, their homogenous particle size, their stability, the ease of production and the potential for manipulation. Virus-like particle possess dynamic structures, their interior is accessible and furthermore the coat is modifiable. Dependent on the application the virus-like particles could have an envelope or not and could be chosen as virus simulators. These embodiments could be used as new biological entities or targets, as vaccines, as antigens for antibody production, as research tools, as diagnostic tool, for drug delivery and bioconjunctions. These virus simulators are formed by self-assembly of envelope and or capsid proteins of many viruses. The size varies between 22-150 nm dependent on the morphology of the particular virus. The virus simulators are non-infectious because they assemble without incorporating genetic material. Dependent on the application foreign genetic material could be included in the herein described virus simulator.

[0003] A promising application of these virus simulators is the production of vaccines against various diseases because their repetitive, high density display of epitopes elicit often a strong immune response. The small size of particles is an advantage for uptake by dendritic cells. Chimeric virus simulators offer an enormous potential in selective, multi-epitope, multi-protein, multi-serotype, multi-strain, or multi-species presentation.

[0004] There exist many expression systems for the production of virus simulators which include the baculovirus/insect cell system, various mammalian cell lines, either stably or transiently transfected or transduced with viral expression vectors, furthermore various species of yeast including *Saccharomyces cerevisiae* and *Pichia pastoris*, and *Escherichia coli* and other bacteria.

[0005] Vaccination is dependent on the generation of a sufficient immunity to protect from infectious diseases. The mostly used attenuated virus vaccines rely on limited replication of the virus in the host following immunization. But this kind of vaccination may cause severe reactions in some patients. Therefore the development of virus-like particles (VLP) as subunit vaccines is an advantage because the particles lack in general DNA or RNA genome but have the authentic conformation of the natural virus.

[0006] Vaccination is one of the most potent and cost-effective counter-measures to the threat of e.g. seasonal or pandemic influenza outbreaks. The ease of spread as an aerosol and the cause for a severe illness especially to susceptible humans are the major reasons why influenza is one of the most devastating viral diseases. Currently licensed seasonal vaccines are only partially protective, and the egg-based production is very time-consuming and cost-intensive. This strategy is vulnerable to the unanticipated emergence of epidemic

strains that are poorly matched or not matched at all by the vaccine. Due to the danger of emerging strains of avian influenza or influenza of other origin novel vaccine approaches are necessary.

[0007] In another aspect the research in the field of several important viruses like HCV, HIV, Ebola etc. is very difficult because of biosafety issues. Until now there exist only a few models for investigation of viral entry and viral trafficking. Diagnostic tools are based on the genome of these viruses because of the lack of appropriate non-infectious virus models.

[0008] Presently commercial human influenza vaccines contain hemagglutinin as their only or main viral antigen. Their production starts from viruses grown on embryonated chicken eggs or, more recently, in mammalian cells in tissue culture. The production in eggs requires selection of high yield, reassorted virus strains, is limited in capacity, time-consuming (6-8 months), and expensive. Beyond that it can cause problems in vaccinated persons allergic to egg protein. The production is only possible with non-lethal bird strains. One of the most important disadvantages of the egg-based production is the limited capacity. In case of a pandemic the production of the seasonal influenza vaccine has to be stopped in favour of a pandemic influenza vaccine production which could result in even more lethal events in the long run.

[0009] Vaccines against viral diseases rely traditionally on attenuated virus strains or inactivation of infectious virus. An appropriate environment is necessary for highly pathogenic or haemorrhagic viruses which constrains the production possibilities because of the biosafety level (e.g. BL3/BL4). For some viruses like human papilloma virus the attenuation will not be sufficient because the virus cannot be propagated in vitro. The ability to generate human papilloma virus (HPV)-like particles based vaccines (Gardasil, Cervarix) has changed the prospects for preventing cervical cancer in woman.

[0010] Due to the danger of emerging strains of avian influenza or other origin, novel vaccine approaches are necessary which result in an enhanced protection.

SUMMARY OF THE INVENTION

[0011] The invention relates to a recombinant virus-like particle comprising two or more different epitopes or different proteins comprising epitopes which are selected either (a) from different viral strains of the same virus and/or (b) from different serotypes of the same virus and/or (c) from different viral strains specific for different hosts. These recombinant virus-like particles are useful as vaccines, and the invention also relates to these vaccines.

[0012] Furthermore the invention relates to a vector comprising two or more polynucleotides coding for different epitopes or for different proteins comprising epitopes which are selected either (a) from different viral strains of the same virus and/or (b) from different serotypes of the same virus and/or (c) from different viral strains specific for different hosts, and to host cells comprising these vectors.

BRIEF DESCRIPTION OF THE FIGURE

[0013] FIG. 1: Schematic representations of vector constructs expressing multiple-epitope virus-like particles.

[0014] (A) (SEQ ID NO:1) Multivalent influenza A virus simulator containing different epitopes (M1, M2) from H1N1 viral strains as well as H3N2 (HA, NA) viral strains

[0015] (B) (SEQ ID NO:2) Chimeric human papilloma virus-like particle containing an epitope (L1) from serotypes HPV16 and HPV18

[0016] (C) (SEQ ID NO:3) Expression vector construct with embedded epitopes (HA, NA, M1, M2) from influenza B/Florida isolates

[0017] (D) (SEQ ID NO:4) Vector construct for expression of an epitope (L1) of HPV16 and HPV18 serotypes where both genes are under the control of different promoters

[0018] (E) (SEQ ID NO:5) Same Vector construct as (B) with deletion of promoter p10

[0019] The vectors contain two promoters P1 and P2 (<,>) selected from polh, p10 and *p_{XIV}* very late baculoviral promoters, vp39 baculoviral late promoter, vp39polh baculoviral late/very late hybrid promoter, pca/polh, pcna, eif, p35, egt, da26 baculoviral early promoters; CMV, SV40, UBC, EF-1, RSVLTR, MT, *P_{DS47}*, Ac5, *P_{GAL}* and *P_{ADH}*. The terminator sequences T1 and T2 (T) are selected from SV40, HSVtk or BGH (bovine growth hormone). Furthermore the vector contains the transposon sites TnL and TnR (L,R) for generation of MultiBacbacmid, a loxP site (LP) for site specific homologous recombination (plasmid fusion), an origin of replication (O), ampicillin (A) and gentamycine (G) resistance genes and defined restriction sites.

[0020] FIG. 2: Analysis of expressed chimeric influenza virus-like particles.

[0021] (A) The conformation of secreted (A, lane 2) as well as intracellular VLPs (prepared from SEQ ID NO:1, A, lane 1) is verified by immunoblotting using specific antibodies against the proteins HA (H3), NA (H3) and M2 (H1). Lane 3=ladder, protein sizes in kDa. The epitopes are co-localized, which means that they are assembled in one particle.

[0022] (B) Visualization of the chimeric Influenza virus-like particle (prepared from SEQ ID NO:3) by electron microscopy using negative staining with uranyl acetate. The spikes representing epitope HA are visible. The size of the particle is in the range of 50-80 nm.

[0023] FIG. 3: Chromatographic purification and analysis of secreted multi-epitope influenza virus-like particles prepared from SEQ ID NO:1.

[0024] (A) Chromatogram of gel filtration purification. The first peak (1) contains the virus-like particle (VLP). The other peaks (2-6) represent contaminant proteins.

[0025] (B) Coomassie-stained SDS-PAGE. The multiple epitopes of the virus-like particles are verified by analyzing different fractions from the 1st peak (1) representing the start (lane 1), middle (lane 2) and end (lane 3) part of the VLP containing peak. The ladder [kDa] is represented left of the first lane. Detection of epitopes is indicated by arrows.

[0026] (C) Western blot analysis according to Coomassie-stained gel using an anti-HA antibody.

[0027] FIG. 4: Functionality of nature-like influenza virus-like particles (VLP).

[0028] Twofold serial dilution series (1:2 to 1:2048) of the purified VLPs (prepared from SEQ ID NO:3) are analyzed by standard hemagglutination assay. 50 μ L purified particle solution was coated onto 96-well plate incubated with red blood cells (erythrocytes). The influenza VLP (1, upper part) are able to agglutinate red blood cells in a dose dependent manner.

[0029] Highest dilution is 1:1024. In contrast PBS, used as control (C), leads only to precipitation of erythrocytes, visible as a "dot" in the middle of the well.

[0030] FIG. 5: In vivo evaluation of multi-epitope influenza virus-like particles.

[0031] Mice are immunized either with 50 ng (mice 1-5) or 100 ng (mice 6-10) purified VLP prepared from SEQ ID NO:3, and as control with PBS (mice 11-12). Antibody titers after prime injection (3 weeks post injection) are indicated as white boxes, titers after a boost injection are indicated as black boxes (6 weeks post injection). The titers are presented as dilution of mice sera (y-axis). VLPs effectively stimulate an antibody immune response. The best results are obtained when immunization is performed with 100 μ l (mice 6-10), indicating a dose dependent immune response. A clear increase of the amount of anti-VLP antibodies is observed after boost. As expected, control animals (mice 11-12) showed no immune response.

[0032] FIG. 6: Confirmation of specific immune response to multi-epitope influenza VLP by hemagglutination inhibition assay.

[0033] The ELISA test was performed with sera taken at week 6 post injection to analyze the presence of specific anti-HA antibodies. Multi-epitope virus-like particles prepared from SEQ ID NO:3 were coated onto a 96-well plate, mixed with the sera and incubated for 30 min. The sera were tested in a series of twofold dilutions (1:2 to 1:1024). After incubation erythrocytes were added and incubated for further 30 min. Specific anti-Influenza-HA antibodies from different mice binding to multi-epitope virus-like particles result in inhibition of erythrocyte agglutination up to a dilution 1:128 (1) and dilution 1:256 (2), visible as erythrocyte precipitation ("dot") in the middle of the well. No hemagglutination inhibition is observed with sera sample of the control mouse (C).

[0034] FIG. 7: Screening of best expression conditions using 50 mL bioreactors.

[0035] The initial cell amount in the range of 1-2 \times 10⁶ cells/mL (TOI, 1 or 2), virus inoculum (MOI, 0.01-2) and time of harvest (days post infection, d2-d6) were determined by dot blot analysis.

[0036] (A) Determination of best expression parameters of an expression construct carrying only one epitope L1 which is used as control. Detection by a specific anti-HPV18 antibody (Abcam).

[0037] (B) Determination of best expression parameters of a multi-epitope expression construct carrying two epitopes from different serotypes (SEQ ID NO:2). Detection by specific anti-HPV16-(Camvir, Santa Cruz) and anti-HPV18-(Abcam) antibodies against the two epitopes HPV16 L1 and HPV18 L1.

[0038] FIG. 8: Chromatographic purification and analysis of multi-epitope human papilloma virus-like particles prepared from SEQ ID NO:2.

[0039] (A) Chromatogram of anion exchange chromatography using DEAE-sepharose column. Flow through (1), wash (2) and elution peaks (3-5) are indicated by numbers (1-5). The increased ionic strength of elution buffer is shown by a line [%]. 3=elution with 300 mM NaCl, 4=elution with 420 mM NaCl, 5=elution with 680 mM NaCl.

[0040] (B) Coomassie-stained SDS-PAGE. The presence of multiple epitopes of the virus-like particles were verified by analyzing different parts of the chromatogramm. Lane 1=ladder [kDa], lane 2=VLP before purification, lane 3=wash step, lane 4=elution with 300 mM NaCl, lane 5=elution with 420 mM NaCl, lane 6=elution with 500 mM NaCl, lane 7=elution with 680 mM NaCl. Epitopes are indicated by arrows (L1).

[0041] (C) Western blot analysis with coomassie-stained gel using specific antibodies against two epitopes which are indicated by arrows (L1).

DETAILED DESCRIPTION OF THE INVENTION

[0042] The invention aims at producing novel virus-like particles for use as vaccines, diagnostic tools and R&D tools based on recombinant DNA and cell cultivation techniques for production. Particles of the invention meet the demand for vaccines suitable to combat a potential pandemic influenza outbreak. The recombinant virus-like particles of the invention are assembled by polypeptide chains that incorporate several, in particular two or more, such as two, three, four or five, or also multiples of three, such as six, nine or twelve, different epitopes or different proteins comprising epitopes which are selected either (a) from different viral strains of the same virus and/or (b) from different serotypes of the same virus and/or (c) from different viral strains specific for different hosts. These epitopes are then displayed on the particle surface. Selection of epitopes from different strains, serotypes and/or viruses specific for different hosts results in a multifunctional virus-like particle mimicking natural changes of viruses as they occur in nature, e.g. as observed in April 2009 during the outbreak of swine influenza. State of the art virus-like particles are either composed of a single protein or comprise up to three different epitopes derived from the same viral strain. The particle of the invention is encoded by a single DNA vector, either viral or plasmid based, which is used for the production in a host cell such as insect cells, bacterial cells and mammalian cells. In a preferred embodiment, the DNA vector is a baculovirus vector and the host cell an insect cell.

[0043] Epitopes of the invention are immunogenic peptides consisting of between 4 and 1000 amino acids, preferably between 6 and 100 amino acids, and are preferably neutralization epitopes. Neutralization epitopes are epitopes which, when bound by antibodies as the results of an immunogenic response, lead to neutralization of the virus carrying such a neutralizing epitope. Epitopes as understood herein may be repetitive, and may be part of a larger protein, in particular part of an antigen, part of a viral surface protein or part of a viral membrane protein. Such epitopes incorporated in viral surface proteins or viral membrane proteins are preferred. If the intended use of the virus-like particles according to the invention is as a R&D tool, diagnostics tool or a virus simulator it is important that the epitopes are part of complete viral proteins providing a complete virus-type surface.

[0044] Different viral strains of the invention are, for example, different strains of influenza virus, for example influenza virus A strains H1N1, H5N1, H9N1, H1N2, H2N2, H3N2 or H9N2, or also influenza virus B or influenza virus C.

[0045] Different serotypes of the invention are, for example, different serotypes of human papilloma virus (HPV), for example serotypes 6, 11, 16, 18, 31, 33, 35, 39, 45, 48, 52, 58, 62, 66, 68, 70, 73 and 82, but also from the proto-oncogenic types HPV 5, 8, 14, 17, 20 and 47 or from papilloma relevant types HPV 6, 11, 13, 26, 28, 32 and 60.

[0046] Virus strains specific for different hosts means particularly adapted to the corresponding host, and are, for example, human influenza virus strains, swine influenza virus strains and avian influenza virus strains. In this context, specific for a host means that the virus is easily transmitted from one host to another host of the same type, but not to a different

type of host. For example, an avian virus strain is easily transmitted from birds to other birds, but not to other animals or to humans.

[0047] In a preferred embodiment the particle comprising epitopes from different strains, serotypes and/or viruses specific for different hosts are combined with B- and/or T-cell epitopes in order to induce a broader immune response.

[0048] In another preferred embodiment the virus-like particle consists of proteins forming a complete virus-like surface, optionally further comprising capsid and nucleopore proteins. The virus-like particle of the invention may further comprise fluorescent proteins, proteins useful for purification purposes of the particles or for attaching a label, and proteinaceous structures required for transport processes and stability.

[0049] The herein described polypeptides and virus like particles are generated in a shorter time and in unlimited amounts compared to actual vaccine manufacturing processes, due to the use of specific genetic and process engineering tools. The capability to assemble the required viral genes by modern molecular biology methods, such as the MultiBac technology (WO 2005/085456; I. Berger et al., Nature Biotechnology 22, 1583, 2004), Polybac technology (WO 2007/054250), or gene synthesis, for instance, allows for fast assembly of the coding DNA vector. The use of these technologies does not require any physical transfer of original, potentially dangerous viruses during the development, manufacturing or administration of virus-like particles and vaccines of the invention. For the construction of particles of the invention it is sufficient to use nucleotide sequences from an infected individual. This stands in major contrast to classical egg-based methods for generating vaccines, which require genetically modified virus as a seed-strain virus. Particles of the invention are manufactured using modern disposable tissue culture techniques which allow for high production capacity. In the preferred embodiment of baculoviral vector and insect cells as host cells the manufacturing process can be quickly set-up, and production times are short, i.e. in the range of weeks rather than months compared to egg-based methods. Additionally, the construction of disposable tissue culture facilities is less time-consuming and costly compared to setting up an egg-based facility. As a consequence large amounts of vaccine for a full population can be produced and re-produced within short time frames, and several different types of vaccines, e.g. seasonal influenza vaccines and pandemic influenza vaccines, can easily be produced in parallel. Difficult decisions by health authorities for the one or the other vaccine due to capacity limits of egg-based vaccine manufacturing plants will not be required.

[0050] The invention relates to a recombinant virus-like particle comprising two or more, such as two, three, four or five, or also multiples of three, such as six, nine or twelve, different epitopes or different proteins comprising epitopes which are selected either (a) from different viral strains of the same virus and/or (b) from different serotypes of the same virus and/or (c) from different viral strains specific for different hosts. Preferred are recombinant virus-like particle comprising three or more, preferably four or more different epitopes or different proteins comprising epitopes. Likewise preferred are recombinant virus-like particle comprising multiples of three, such as six, nine or twelve different epitopes or different proteins comprising epitopes. The epitopes are selected from two different strains, serotypes or virus strains specific for different hosts, or from three different strains, serotypes or virus strains specific for different hosts, or from

four different strains or serotypes. Preferred are virus-like particles comprising several epitopes from three different strains or serotypes. Likewise preferred are virus-like particles comprising several epitopes from virus strains specific for two or three different hosts.

[0051] Furthermore the invention relates to a vector comprising two or more, such as two, three, four or five, or also multiples of three, such as six, nine or twelve, different polynucleotides coding for epitopes or for different proteins comprising epitopes which are selected either (a) from different viral strains of the same virus and/or (b) from different serotypes of the same virus and/or (c) from different viral strains specific for different hosts. "Polynucleotides" as used herein may represent a chain of between 12 and 3,000 nucleotides, includes oligonucleotides as commonly designated, and may be a viral gene or open reading frame from the mentioned different viral sources, in particular genes or open reading frames encoding viral surface proteins or viral membrane proteins.

[0052] Preferred are vectors coding for preferred virus-like particles mentioned hereinbefore.

[0053] Most preferred is a vector comprising a polynucleotide sequence selected from SEQ ID NO: 1 to 5.

[0054] In preferred embodiments a virus-like particle of the invention comprises

[0055] (1) the same type of a surface protein from two or three different strains or serotypes of the same virus;

[0056] (2) a mixture of more than two different surface proteins from different viral strains, e.g. from influenza virus strains H5N1 and H1N1;

[0057] (3) a mixture of different surface proteins combined from viruses specific for different hosts, e.g. from influenza virus specific for swine, human and/or avian hosts.

[0058] Viruses considered as source for epitopes to be comprised in virus-like particles of the invention are, for example, influenza virus, HPV, HIV, CMV, Dengue, HCV and Newcastle Disease Virus. Epitopes may be derived from other viruses and from bacteria. Particularly preferred is influenza virus. Equally preferred is human papilloma virus (HPV).

[0059] Vectors considered are DNA vectors, and can either be a plasmid vector or a viral vector. Methods to assemble such vectors are standard methods of state of the art molecular biology. Preferred methods are MultiBac such as described in WO 2005/085456 and in I. Berger et al., Nature Biotechnology 22, 1583, 2004, or Polybac methods such as described in WO 2007/054250, combined with CAPTM technology and state of the art gene synthesis technologies. These technologies allow assembling a multi-gene co-expression DNA vector which is suitable for expression in different host cells. The preferred DNA vector of the invention is a baculoviral vector.

[0060] The host cell used for the expression of vectors of the invention can be any prokaryotic (e.g. *E. coli*) or eukaryotic expression cell line. For expression of a preferred baculoviral vector an insect cell line is preferred. Examples of insect cell lines are, e.g., SF9, SF21, Hi-5, Express Sf+, and S2 Schneider cells. For expression in a eukaryotic system, mammalian cells are preferred, in particular human cells, e.g. HeLa, Huh7, HEK293, HepG2, BHK, CHO, MT-2, bone-marrow fibroblasts, primary neural cells, or embryonic cells. For expression in yeast *S. cerevisiae*, *S. pombe*, *C. albicans*, or *P. pastoris* cells may be used.

[0061] Cultivation and propagation of host cells according to the invention can be done in any vessel, bioreactor or disposable unit providing the appropriate conditions for the particular host cell.

[0062] The virus-like particles of the invention can be used as vaccines. Furthermore they may be used as antigens in diagnostic tools, antigens for antibody generation, and as virus simulators for research and development tools, e.g. viral entry studies and virus-host interaction studies.

[0063] Vaccines according to the invention contain the recombinant virus-like particle in aqueous solution optionally further containing viscosity-regulating compounds, stabilizing compounds and/or adjuvants increasing the immunogenicity, as is known in the state of the art.

[0064] In a particular embodiment H3N2 Influenza virus-like particles are constructed using the methods of Berger et al., Nature Biotechnology, 2004, WO2005/085456 and WO 2007/054250 and CAPTM technology. At least one M1 and M2 gene of the H1N1 Influenza strain A/Puerto Rico/834 is cloned by PCR amplification into the transfer vector pFL (WO 2007/054250, FIG. 1) together with the HA gene of influenza A/Brisbane10/2007 and the NA gene of influenza A/Brisbane10/2007. The construct is confirmed by DNA sequencing.

[0065] In another particular embodiment the same cloning techniques are used to introduce at least one L1 gene of both serotypes HPV16 and HPV18 or further serotypes from the group 2, 4, 6, 11, 31, 33-35, 39, 40-45, 51-53, 55-59, 62, 66, 68, 70, 73, and 77, cloned into the transfer vector pFL (FIG. 1).

Experimental Part

[0066] The baculoviral vectors termed MultiBac or YFP-MultiBac (WO 2005/085456), which allow propagation in *E. coli* cells, and CAPTM technology are used for generation of recombinant AcNPVs (*Autographa californica* nuclear polyhedrosis virus, a baculovirus) using a conventional system (Fitzgerald et al., Nature Methods, 3, 1021, 2006). 10 ng of the multi-gene vector is transformed in DH10MultiBac and/or DH10YFPMultiBac competent cells. Positive clones are selected by blue/white screening and PCR. The corresponding MultiBac bacmid DNA is isolated using the Birnboim & Doly method. Recombinant AcNPVs are generated by transfection of 1 µg of multi-gene MultiBac bacmid in 0.9×10⁶ Sf21 (Invitrogen) cells using transfection reagent Fugene (Roche) according to the manufacturers protocol. Virus amplification is done as described previously (Fitzgerald et al., Nature Methods, 3, 1021, 2006). The titer of all recombinant AcNPVs is determined by plaque assay described in the Bac-to-Bac-Manual (Invitrogen). Protein production parameters like multiplicity of infection (MOI), cell number (TOI) and time of harvest (TOH) are analyzed with small scale expression studies.

EXAMPLE 1

Generation of Expression Vector Construct

[0067] To manufacture various constructs the multiplication module M present in the transfer vector pFL (WO 2005/085456 and CAPTM technology) is used according to the described method in WO 2005/085456. DNA of epitopes are either obtained by isolation of viral RNA from original virus followed by reverse transcription combined with PCR (for the influenza virus epitopes) or by gene synthesis (provided by

the company Geneart). The reverse transcription is performed using the RevertAid™ H Minus First strand cDNA Synthesis kit (Fermentas) according to the manufacturer's protocol. The cDNA (2 µL) is used as template for PCR reaction. The following conditions are used based on the manufacturer's protocol. For a 50 µL total volume reaction 0.2 mM dNTP (NEB), 1.2% DMSO, 0.5 µM reverse and forward primer (Microsynth), 10 µL 5×Phusion GC reaction buffer and 2U Phusion Hot Start Polymerase (Finnzyme) are used. For multigene assembly the appropriate restriction sites (BstZ17I, Spel, Pmel, AvrII) are introduced using PCR. The PCR fragments are cut with the restriction enzymes followed by ligation and transformation processes to integrate the multiplication module into the transfer vector. The ligation is done over night at 4°C. using 500 ng linearized transfer vector (pFL), 4 µL PCR product and 1U T4-DNA-ligase (Fermentas). To generate the plasmid 4 µL ligation solution are added to 50 µL competent DH5 α cells and incubated for 30 min on ice. After a heat shock at 42°C. for 30 sec and a 2 min cold shock at 4°C., 200 µL LB medium is added and incubated for 1 h at 37°C. and 220 rpm. Afterwards 80 µL of the cell suspension is plated on LB agar plates containing the appropriate antibiotics, in this case 100 µg ampicillin and 100 µg gentamycin. The whole procedure is repeated until all epitopes are introduced into the transfer vector.

[0068] Influenza epitopes are selected from the genes HA and NA, both chosen from a H3N2/Brisbane10/2007 strain whereas epitopes from M1 and M2 are chosen from H1N1/Puerto Rico/834 strain. The M1 epitope is controlled by the promoter p10, all other epitopes are controlled by the polyhedrin promoter polh. All epitopes are present on the same vector construct (FIG. 1A, SEQ ID NO:1). Influenza B/Florida/2006 isolates are chosen to generate a construct with multiple epitopes from the genes HA, NA, M1 and M2 (FIG. 10, SEQ ID NO:3). Human papillomavirus epitopes are selected from the gene L1 from the cancer relevant serotypes HPV16 and HPV18 and are unified in one vector construct. Both epitopes are controlled by the polyhedrin promoter polh (FIG. 1B, SEQ ID NO:2). To improve the expression yield the p10 promoter is deleted in a further construct (FIG. 1E, SEQ ID NO:5). In another construct HPV16 epitope is controlled by p10 promoter whereas the polyhedrin promoter polh is chosen for the HPV18 epitope (FIG. 1D, SEQ ID NO:4).

EXAMPLE 2

Generation of Recombinant Baculovirus

[0069] This virus contains multiple epitopes to generate virus-like particles or virus simulators which present these epitopes on their surface. The virus-like particles can be used for different applications, e.g. as vaccines in the influenza field. The AcNPV-derived baculovirus contains multiple different epitopes from the viral strains recommended by WHO for the 2008/2009-VLP vaccination campaign. All genes of the transfer vector are transposed by site specific homologous recombination into MultiBac cells according to the protocol of WO 2005/085456.

[0070] 10 ng transfer vector are added to 100 µL MultiBac competent cells and incubated for 30 min at 4°C. After a heat shock at 42°C. for 45 sec and a 2 min cold shock at 4°C. 400 µL LB medium is added and the cell solution is incubated for 4 h at 37°C. and 220 rpm. Different dilutions are plated on appropriate LB agar plates containing various antibiotic resistances. Based on blue/white and PCR screening several

correct MultiBac clones are selected. The corresponding MultiBac bacmid DNA is isolated using the Birnboim & Doly method. At least four MultiBac bacmid clones are selected for initial transfection of insect cells like Sf9 or Sf21 to generate the recombinant AcNPV-derived baculovirus. This is generated by transfection of 1 µg of multi-gene MultiBac bacmid in 0.9×10⁶ Sf21 (Invitrogen) cells using transfection reagent Fugene (Roche) according to the manufacturer's protocol. Virus amplification is done as described previously (Fitzgerald et al., Nature Methods, 3, 1021, 2006; Bac-to-Bac-Manual, Invitrogen). The virus is amplified to expand the volume and increase the infectious titer which is determined by plaque assay according to Bac-to-Bac-Manual (Invitrogen). The best expression construct is determined by 50 mL small scale expression experiments followed by determination of protein yield by Bradford Assay (ADV, Cytoskeleton). Expression of best expressor is further verified by Western blot analysis with antibodies against the multiple different epitopes (FIG. 2A).

EXAMPLE 3

Production and Purification of Multi-Epitope Influenza Virus-Like Particles in Insect Cells

[0071] After determination of the best expression construct the biotechnological production parameters like cell line, cell amount (TOI), amount of recombinant virus inoculum (multiplicity of infection, MOI) and time of harvest (TOH) are determined in 50 mL bioreactors. A matrix of different TOI, MOI and TOH are designed according to Eibl, Riesen and John (Bioforum 03/2009) and Friesen J. (Bachelor thesis, University of Applied Science, Esslingen, Germany). The expression of secreted or intracellular multi-epitope virus-like particles is observed for six to eight days with daily sample taking. For intracellular particles (e.g. HPV) the cell pellets are lysed with 50 mM TrisCl, pH 7.6, 100 mM NaCl, 0.1%TritonX100 and centrifuged for 10 min, at 4°C. and 8000×g. The epitopes of the virus-like particles present in the supernatant are further verified using a Dot-blot apparatus (Biometra) followed by Western blotting with specific antibodies. Conditions resulting in the highest yield are defined as expression parameters preferring a harvest time between three and four days. According to these defined parameters the virus-like particles are produced either in shaker flasks or wave cultibags in fall armyworm *Spodoptera frugiperda* cells Sf9 and Sf21. For multi-epitope influenza virus-like particles expression Sf21 cells are chosen with the following conditions: 1.5×10⁶ cells/mL, MOI 0.05 and harvest time at day four post infection. Cells are propagated at 27°C. without carbon dioxide and fetal calf serum supplementation. According to defined time of harvest the secreted virus-like particles are collected by centrifugation at 500-1000×g for 20 min at 4°C. The supernatant volume containing the particles is reduced for purification by tangential flow filtration using cassettes (Sartocon-Slice 200, Sartorius and CentramateOS, PALL) with a cut-off of 100 kDa. The purification of virus-like particles is performed with scalable chromatographic methods and sucrose gradient ultracentrifugation.

[0072] The chromatographic purification is a multi-step purification using cation exchange, anion exchange and gel filtration chromatography. The supernatant is loaded onto a CattoQ column connected to an FPLC-system (AEKTA purifier, GE Healthcare) in 50 mM phosphate buffer, pH 7.4. The particles are eluted with increasing salt concentrations in

a linear gradient using 50 mM phosphate, 1 M NaCl, pH 7.4. The particle containing fractions are pooled and further purified by gel filtration chromatography (VLP from SEQ ID NO:1, FIG. 3). The purification is performed in 50 mM phosphate, 150 mM NaCl, pH 7.4 buffer using a HighLoad Superdex 200 pg column. All chromatography steps are analyzed by SDS-PAGE followed by coomassie staining and immunoblotting.

EXAMPLE 4

Analysis of Purified Influenza Virus-Like Particles

[0073] To confirm the presence of the different epitopes purified material is analyzed by SDS-PAGE followed by coomassie staining or Western blot. 150 µl of different chromatography fractions are loaded on a 4-12% Bis-Tris NuPAGE gel (Invitrogen), run for 15 min at 150V and for 45 min at 175 V and coomassie stained using SimplyBlueSafeStain (Invitrogen). For immunoblotting the proteins are transferred onto a nitrocellulose membrane (BioRAD) at 19 V for 40 min using a semi-dry apparatus (BioRAD). After blocking unspecific binding sites for 30 min with 5% non-fat-dry-milk-TrisCl-Tween20 (0.1%) solution, the membrane is incubated over night at 4°C. with antibodies against HA, NA and matrix proteins. The membrane is washed several times with TrisCl-Tween20 (0.1%) buffer. Dependent on the source of primary antibody the second antibody is either an anti-mouse or anti-rabbit connected with alkaline phosphatase or horse-radish-peroxidase for detection. A co-localization of these proteins show the assembly and the production derived from one expression vector and one baculovirus (FIG. 3B, from SEQ ID NO:1). This co-localization can also be shown for the expression constructs containing the genes HA, NA and both matrix proteins M1 and M2 including their membrane anchors.

EXAMPLE 5

Functionality of Influenza Virus-Like Particles (VLP)

[0074] To analyze if the VLPs correctly integrate the hemagglutinin protein (HA) in their surface, a standard hemagglutination assay using red blood cells (RBC) from chicken is performed (FIG. 4, VLP from SEQ ID NO:3). Twofold serial dilutions of the purified VLPs are carried out with PBS (1×) in V-formed 96 well plates. An equal amount of erythrocytes (1% solution) is added and incubated for 1 h at 4°C. The appearance of RBC aggregates on the bottom of the well indicates lack of hemagglutination. Titers are expressed as the inverse of the highest dilution of the purified VLP solution to agglutinate RBCs. The results obtained show that VLPs are able to agglutinate chicken erythrocytes and demonstrate indirectly the presence of HA on the VLP surface. The negative control (PBS) shows no agglutination.

EXAMPLE 6

In vivo Evaluation of Influenza VLP

[0075] The immunogenicity (stimulation of immune system) of VLPs (prepared from SEQ ID NO:3) is tested in vivo using two groups of mice which are subcutaneously immunized in a prime boost schedule at week 0 and week 3 respectively. Immunization is performed using 50 or 100 µl (50 or 100 ng) of VLPs in suspension. To determine the quality of

the immune response of the VLPs alone, no adjuvant is used. Mice are bled at week 3 and 6 and sera are analyzed to look for antibody responses against the immunized VLPs. Results obtained show that VLPs are effective at stimulating an antibody immune response. The best results are obtained when immunization is performed with 100 µl, indicating a dose dependent immune response. A clear increase of the amount of anti-VLP antibodies is observed after boost. As expected, naïve animals show no immune response.

[0076] To reconfirm the specificity of the immune response, a hemagglutination inhibition test is performed at week 6 to analyze the presence of specific anti-HA antibodies. The results show that specific anti-Influenza-HA antibodies are able to inhibit erythrocyte agglutination up to a dilution 128 (mouse 6) and a dilution 256 (mouse 8). No hemagglutination inhibition is observed with sera sample of the naïve mouse. Newly generated multi-epitope influenza-VLPs are able to stimulate the immune system in a dose dependent manner. When the immune system is re-stimulated with a boost, the immune response increases at least 15 times. The specificity of the elicited immune response is analyzed by ELISA and a hemagglutination test.

EXAMPLE 7

Production and Purification of Multi-Epitope Virus-Like Particles Carrying Human Papillomavirus Epitopes in Various Cell Lines

[0077] The biotechnological production parameters like cell line, cell amount (TOI), amount of recombinant virus inoculum (multiplicity of infection, MOD and time of harvest (TOH) are determined in 50 mL bioreactors (FIG. 7) according to Eibl et al. (Bioforum 3/2009). According to these defined parameters the virus-like particles are produced either in shaker flasks or wave cultibags in fall armyworm *Spodoptera frugiperda* cells Sf9 and Sf21. Multiple-epitope papilloma virus-like particles are expressed from SEQ ID NO:2 in Sf21cells using 2×10^6 cells/mL, MOI 0.5 and harvest time at day three post infection. Cells are propagated at 27°C. without carbon dioxide and fetal calf serum supplementation. At defined harvest time (three days post infection) intracellular virus-like particles are collected by centrifugation at 500-1000×g for 20 min at 4°C. The cells are lysed using hypotonic phosphate buffers followed by ultrasonication. After a centrifugation step at 4°C. and 2000×g the supernatant was collected. The purification of virus-like particles is performed with scalable chromatographic methods and sucrose gradient ultra-centrifugation. The chromatographic purification is a multi-step purification using cation exchange, anion exchange and gel filtration chromatography. The supernatant is loaded onto a CattoDEAE column connected to an FPLC-system (AKTA purifier, GE Healthcare) in 50 mM phosphate buffer, pH 7.4. The particles are eluted with increasing salt concentrations in a linear gradient using 50 mM phosphate, 1 M NaCl, pH 7.4 (FIG. 8A). The particle containing fractions are pooled and further purified using a hydroxyapatite column. Binding is performed in 20 mM phosphate buffer, pH 7.0 followed by linear gradient elution with 500 mM phosphate, 150 mM NaCl, pH 7.0. To polish the multi-epitope particles a gel filtration chromatography is done. The purification is performed in 50 mM phosphate, 150 mM NaCl, pH 7.4 buffer using a HighLoad Superdex 200 pg

column. All chromatography steps are analyzed by SDS-PAGE followed by coomassie staining and immunoblotting.

EXAMPLE 8

Analysis of Purified Chimeric Human Papilloma Virus-Like Particles

[0078] To confirm the presence of the different epitopes in purified material, the VLP prepared from SEQ ID NO:2 is analyzed by SDS-PAGE followed by coomassie staining (FIG. 8B) and Western blot (FIG. 8C). For immunoblotting antibodies against L1 protein of different serotypes are used. 150 μ l of different chromatography fractions are loaded on a 4-12% Bis-Tris NuPAGE gel (Invitrogen), run for 15 min at 150 V and a for 45 min at 175 V and coomassie stained using SimplyBlueSafeStain (Invitrogen). For immunoblotting the proteins are transferred onto a nitrocellulose membrane (Bio-RAD) at 19 V for 40 min using a semi-dry apparatus (Bio-RAD). After blocking unspecific binding sites for 30 min with 5% non-fat-dry-milk-TrisCl-Tween20 (0.1%) solution, the membrane is incubated over night at 4° C. with antibodies against L1 epitopes. Camvir antibody (SantaCruz) is used for HPV16 and anti-HPV18ab (Abcam) for HPV18 detection.

The membrane is washed several times with TrisCl-Tween20 (0.1%) buffer. The membrane is incubated for 1 h with an anti-mouse antibody connected with alkaline phosphatase for detection. The epitopes are detected by BCIP/NPT solution. A co-localization of these proteins show the assembly and production derived from one expression vector and one baculovirus.

EXAMPLE 9

Functionality of Chimeric Human Papilloma Virus-Like Particles (VLP)

[0079] To analyze if the human papilloma virus-like particles prepared from SEQ ID NO:2 correctly integrate the L1 protein in their surface, a standard ELISA assay is performed. Twofold serial dilutions of the purified VLPs are carried out with PBS (1 \times) in V-formed 96 well plates. An equal amount of a serotype specific antibody (concentration 1:1000) is added and incubated for 1 h at 37° C. Appropriate binding of the antibody to the L1 protein is detected using a second antibody with a horse-radish peroxidase and a chemoluminescent detection system. The results obtained show binding of antibodies to the recombinant expressed epitopes in a dose dependent manner. The negative control (PBS) showed no binding.

SEQUENCE LISTING

```

<160> NUMBER OF SEQ ID NOS: 5

<210> SEQ ID NO 1
<211> LENGTH: 10482
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: multi-epitope influenza A virus-like particle

<400> SEQUENCE: 1

ttctctgtca cagaatgaaa attttctgt catctttcg ttattaatgt ttgttaattga      60
ctgaatatca acgcttattt gcagcctgaa tggcgaatgg gacgcgcct gtacggcgc      120
attaagcgcg gcgggtgtgg tggttacgcg cagcgtgacc gctacacttg ccagcgcct      180
agcgcgcgt ctttcgctt tttcccttc ctttctcgcc acgttcgccg gctttccccg      240
tcaagctcta aatcgggggc tccctttagg gttccgattt agtgcgttac ggcacctcg      300
ccccaaaaaa cttgatttagg gtgatggttc acgttagtggg ccacgcgcct gatagacggt      360
tttcgcgcct ttgacgttgg agtccacgtt cttaatagtg gactcttggt ccaaactgg      420
acaacactca accctatctc ggtctattct tttgatttat aaggatttt gccgatttc      480
gcctattgtt taaaaatgt gctgatttaa caaaaattta acgcgaattt taacaaaata      540
ttaacgctta caattttgtt ggcactttc gggaaatgt ggcgcgaacc cctattttgtt      600
tattttctta aatacattca aatatgtatc cgctcatgag acaataaccc tgataaatgc      660
ttcaataata ttgaaaaagg aagagttatgtt gttccgtgtc gcccattttc      720
cctttttgc ggcattttgc cttcctgttt ttgctcaccc agaaacgcgt gtgaaagtaa      780
aagatgtga agatcagttt ggtgcacgag tgggttacat cgaactggat ctcaacagcg      840
gtaagatcct tgagagttt cgcccgaaag aacgtttcc aatgtatgagc acttttaag      900
ttctgctatg tggcgccgta ttatccgtt ttgacgcggg gcaagagcaa ctcggcgcc      960

```

-continued

gcatacacta ttctcagaat gacttgggt gactactacc agtcacagaa aagcatctta 1020
cgatggcat gacagtaaga gaattatgc gtgctgccat aaccatgagt gataaacactg 1080
cgcccaactt acttctgaca acgatcgag gaccgaagg gctaacggct ttttgcaca 1140
acatggggga tcatgttaact cgccctgatc gttggaaacc ggagctgaat gaagccatac 1200
caaacgacga gcgtgacacc acgatgcctg tagcaatggc aacaacggtt cgcaactat 1260
taactggcgactacttaact ctgatccc ggcacaattt aatagactgg atggaggcg 1320
ataaaagtgc aggaccactt ctgcgcctcg ccctcccgcc tggctggttt attgtgata 1380
aatctggagc cggtgagcgt gggtctcgcg gtatcattgc agcaactggg ccagatggta 1440
agccctcccg tatactgttagt atctacacga cggggagtc ggcaactatg gatgaacgaa 1500
atagacagat cgctgagata ggtgcctcac tgattaagca ttggtaactg tcagaccaag 1560
tttactcata tatacttttag attgatttaa aacttattttaa ttaatttaaa aggatctagg 1620
tgaagatcct ttttgataat ctcatgacca aaatccctta acgtgagttt tcgttccact 1680
gagcgtcaga ccccgtagaa aagatcaaag gatcttctt gatccctttt tttctgcgcg 1740
taatctgtc tttgcaaaaca aaaaaccac cgctaccacg ggtgggttgc ttgcggatc 1800
aagagctacc aactctttt ccgaaggtaa ctggcctcag cagagcgcag ataccaaata 1860
ctgttcttc agtgtagccg tagttaggcc accacttcaa gaactctgta gcaccgccta 1920
catacctcgc tctgctaatac ctgttaccag tggctgtgc cagtgccgat aagtcgtgtc 1980
ttaccgggtt ggactcaaga cgatagttac cggataaggc gcagcggctcg ggctgacgg 2040
ggggttcgtg cacacagccc agcttggagc gaacgaccta caccgaactg agataacctac 2100
agcgtgagct atgagaaagc gcccacgttc ccgaaggggaa aaaggcggac aggtatccgg 2160
taagcggcag ggtcggaaca ggagagcgcgca cgagggagct tccaggggaa aacgcctgg 2220
atctttatag ttctgtcggtt ttcgcacc tctgacttgc gctcgatattt ttgtatgtct 2280
cgtcaggggg gcccggccata tggaaaaacg ccagcaacgc ggcctttta cggttctgg 2340
ccttttgcgtg gcttttgcgt cacatgttct ttctgtcggtt atccccgtat tctgtggata 2400
accgttattac cgccttgcg ttagctgata ccgctcgccg cagccgaacg accgagcgc 2460
gcccggatcgt gaggcggagaa gccggaaagac gcctgtatgc gtattttctc cttacgcata 2520
tgtgcggat ttcacaccgc atagaccacg cgctgtaacct ggcaaaatcg gttacgggtt 2580
agtaataataat ggatgcctg cgtaagcggg tggggcggca caataaaatgc tttaactgaa 2640
caaaatagat ctaaaactatg acaataaaatg cttaaacttag acagaatagt tgtaactgaa 2700
aatcagtccca gttatgtctgt gaaaaagcat actggacttt tgttatggct aaagcaact 2760
cttcattttc tgaagtgcata attggccgtc gtatcaaaga gggcgtggc caagggcatg 2820
gttaaagacta tattcggcgc gttgtgacaa ttaccgaaac aactccgcgg cccggaaagcc 2880
gatctcggtt gtaacgaatt gtttaggtggc ggtacttggg tgcataatcaa agtgcatac 2940
tttctcccgat atgcccact ttgtatagag agccactcgcc ggatcgatc cgtatctgc 3000
ttgcacgtatc atcacataag caccacgcg gttggccctca tgcttgagga gattgtatg 3060
cgccggatcgc atgcccgtcc tccggctgc gccggagact gggatcgatcat agatataatg 3120
ctcaactacgc ggctgatcataa acttggccgag aacgtaagcc gggagagcgc caacaaccgc 3180
ttcttggcgatc aaggcggccaa gcccggatcgc tggggatcataa cggagacatg tcccgaggta 3240

-continued

atccggagtcc ggctgatgtt gggagtaggt ggctacgtct ccgaactcac gaccggaaag 3300
atcaagagca gccccatgg atttgacttg gtcagggccg agcctacatg tgcaaatgat 3360
gccccatactt gagccaccta actttgttt agggcactg ccctgtcgta taacatcggtt 3420
gctgctgcgt aacatcggtt ctgctccata acatcaaaca tcgaccacg gcgtaacgcg 3480
cttgctgctt ggatgcccga ggcataagact gtacaaaaaa acagtcataa caagccatga 3540
aaaccgccccac tgccgcgtt ccaccgcgtc gttcggtcaa ggttctggac cagttcgctg 3600
agcgcatacg ctacttgcatt tacagtttac gaaccgaaca ggcttatgtc aactgggttc 3660
gtgccttcat ccgtttccac ggtgtgcgtc acccggcac cttggcagc agcgaagtcg 3720
aggcatttct gtcctggctg gcgaaacgago gcaaggttcc ggtctccacg catcgtcagg 3780
cattggccgc cttgctgttc ttctacggca aggtgctgtg cacggatctg cccttgcgtt 3840
aggagatcg tagacacctgg ccgtcgccgc gcttgcgggt ggtgtgcacc ccggatgaaag 3900
tggttcgcat cctcggtttt ctggaaggcg agcatcgttt gttcgccag gactctagct 3960
atagttctag tggttggcta cagcttgtt tgtactatca acaggttggaa ctgctgatca 4020
acagatccctc tacgcggccg cggtaaccata acttcgtata gcatacattta tacgaagtt 4080
tctggtttaa acgttacccgt agtggctatg gcagggcttg ccggcccgac gttggctgcg 4140
agccctgggc cttcacccga acttgggggt tgggggtggg aaaaggaaaga aacgcggggcg 4200
tattggtccc aatggggtct cgggtgggta tcgacagagt gccagccctg ggaccgaacc 4260
ccgcgtttat gaacaaacga cccaaacaccc gtgcgtttta ttctgtctt ttattggccgt 4320
catagcgcgg gttccttcg gtattgtctc cttccgtgtt tcagttagcc tccccatct 4380
cccggtacccg catgctatgc atgcggccgc tcacttgaac cgttgcacatc gcaccccat 4440
tcgtttctga taggcctgca aattttcaag aagatcattt ttcagaccag cactggagct 4500
aggatgagtc ccaatggttc tcatcgcttgc caccatttgc cttagctgac tagcaaccc 4560
catggcctctc gctgcttgct cactcgatcc agccatttgc tccatagctt tagctgttgt 4620
gctggctaaaccattctgt tctcatgtct gattgtggaa ttgggtgttg tcaccatttg 4680
cctatgagac cgatgctggg agtcagcaat ctgttcacag gttgcacata ccaggccaaa 4740
tgccacttca gtggtcacag ccccatctt gttgtatatg agggccatc aactggcaag 4800
tgcaccagca gaataactga gtgagattt tttggccca tggaaatgtta tctcccttt 4860
gagcttccta tacagttaa ctgcttgctc catgttattt ggatccccgt tcccattaag 4920
ggcagttgg acaaagcgctc tacgtgcag tccctgcctca ctgggcacgg tgagcgtgaa 4980
cacaatccctt aaaaatccct tagtcagagg tgacaggattt ggtcttgcgtt ttacccattc 5040
catgagaacc tcaagatccg tgttttttcc tgcacaaagaca tcttcaagtc tctgtgcgt 5100
ctcggttttgg agggggccctg acggggatgtt agagagaacg tacgtttcgat cctcggttag 5160
aagactcatg gtggatccat cccgggtgtt caagtcttcg tgcgtgtt gtaaaaaaaa 5220
tgtaattttac agtataatgtt ttttaattat atacaaatgtt tttgtataata attcttattt 5280
aactataata tattgtgtt ggtgaattt aaggccgtt tacttagtac gattccgcac 5340
ctactccggat atattaatag atcatggaga taattaaat gataaccatc tcgcaataaa 5400
ataagtattt tactgttttgc gtaacagttt tgtaataaaa aaacctataa atattccggat 5460
ttattccatc cgtccccacca tcgggcggccg atccaccatc aatccaaatc aaaagataat 5520

-continued

aacgattggc tctgtttctc tcaccatttc cacaatatgc ttcttcatgc aaattgccat	5580
cttgataact actgtacat tgcatttcaa gcaatatgaa ttcaactccc ccccaaacaa	5640
ccaagtatg ctgtgtgaac caacaataat agaaagaaac ataacagaga tagtgtatct	5700
gaccaacacc accatagaga aggaaatatg ccccaaacta gcagaataca gaaattggtc	5760
aaagccgaa tgtgacatta caggattgc accttttct aaggacaatt cgattaggct	5820
ttccgctggt ggggacatct ggggacaaag agaaccttat gtgtcatgcg atcctgacaa	5880
gtgttatcaa tttgccctg gacagggaaac aacactaaac aacgtgcatt caaatgacac	5940
agtacgtgat aggaccctt atcggaccctt attgatgaat gagtttaggtg ttccctttca	6000
tctggggacc aagcaagtgt gcatagcatg gtccagctca agttgtcact atggaaaagc	6060
atggctgcat gtttgtataa cggggatgta taaaatgca actgttagct tcatttacaa	6120
tggaggcctt gtagatagta ttgtttcatg gtccaaagaa atcctcagga cccaggagtc	6180
agaatgcgtt tggatcaatg gaacttgtac agtagataatg actgtatggg gtgcattcagg	6240
aaaagctgat actaaaatac tattcattga ggaggggaaa atcgttatac ctagcacatt	6300
gtcaggaaatg gtcagcatg tcgaggatgt ctccctgtat cctcgatatc ctgggttcag	6360
atgtgtctgc agagacaact ggaaaggctc caataggccc atcgtagata taaacataaa	6420
ggatcatagc actgtttcca gttatgtgtg ttcaaggactt gttggagaca caccagaaaa	6480
aaacgacagc tccagcagta gccattgttt ggatcctaac aatgaagaag gtggcatgg	6540
agtgaaaggc tgggccttgc atgatggaaa tgacgtgtgg atggaaagaa cgatcagcga	6600
gaagtcgcgc ttagggatgt aaacatttcaa agtcattgaa ggctggtcca accctaagtc	6660
caaattgcag ataaataggc aagtcatagt tgacagaggt aataggccg gttattctgg	6720
tatattctct gttgaaggca aaagctgcat caatcggtgc ttttatgtgg agttgataag	6780
ggaaagaaaa gggaaactg aagtctgtg gacctaacc agtattgtt gttttgtgg	6840
cacccatggc acatatggaa caggctcatg gcctgatggg gcccacatca atctcatgcc	6900
tatataagta cttagggatc ataatcagcc ataccacatt tgcattgtt ttacttgctt	6960
taaaaaaccc cccacaccc cccctgaacc tgaaacataa aatgaatgca attgttgc	7020
ttaacttgc tattgcattgtt tataatgggtt acaaataaag caatgcatac acaaatttca	7080
caaataaaagc attttttca ctgcattcta gttgtggtt gtccaaactc atcaatgtat	7140
cttatcatgt ctggatctga tcactgttgc agcctagaag atccggctgc taacaaagcc	7200
cggaaaggaaatg ctgagttggc tgctgtggct agcttatcta gaaatataa tagatcatgg	7260
agataattaa aatgataacc atctcgaaat taaataagta ttttactgtt ttgcataacag	7320
ttttgtataata aaaaaaccta taaatattcc ggattattca taccgtccca ccateggcg	7380
caccatgagt cttctaaaccg aggtcgaaac gcctatcaga aacgaatggg ggtgcagatg	7440
caacgggtca agtgcatttc tcactattgc cgcaaatatc attggatct tgcaattgc	7500
attgtggatt cttgtatgtc ttttttcaatgcatttac cgatgttttca aatacgact	7560
gaaaggaggg cttctacgg aaggagtgc aaggtctatg agggaaagat atcgaaagga	7620
acagcagatg gctgtggatg ctgacgtatgc tcatgttgc agcatagac tggagtaatg	7680
actagaggat cataatcagc cataccacat ttgttagaggt tttacttgct taaaaaaacc	7740
tcccacaccc cccctgaac ctgaaacataa aatgaatgc aattgttgc ttacttgctt	7800

-continued

ttattgcagc ttataatggt tacaataaaa gcaatagcat cacaaatttc acaaataaag	7860
cattttttc actgcattct agttgtggtt tgtccaaact catcaatgta tcttatcatg	7920
tctggatctg atcaactgctt gaggctagaa gatccggctg ctaacaaagc ccgaaaggaa	7980
gctgagttgg ctgctgccac cgctgagcaa taactatcat aaccggaata ttaatagatc	8040
atggagataa taaaatgtat aaccatctcg caaataaata agtattttac tgttttcgta	8100
acagttttgt aataaaaaaaa cctataaata ttccggattt ttcataccgt cccaccatcg	8160
ggcgccgatc caccatgaag actatcattt ctttgagcta cattctatgt ctggtttca	8220
ctcaaaaact tcccgaaat gacaacagca cggcaacgt gtgccttggg caccatgcag	8280
taccaaacgg aacgatagtg aaaacaatca cgaatgacca aattgaagtt actaatgcta	8340
ctgagctggt tcagagttcc tcaacaggtt aaatatgcga cagtcctcat cagatccttgc	8400
atggagaaaa ctgcacacta atagatgctc tattggaga ccctcagtgt gatggttcc	8460
aaaataagaa atgggacattt tttgttgaac gcagcaaagc ctacagcaac ttttaccctt	8520
atgatgtgcc ggattatgcc tcccttaggt cactagttgc ctcateccgc acactggagt	8580
ttaacaatga aagcttcaat tggactggag tcactcaaaa cggacaacaagc tctgettgca	8640
taaggagatc taataaacagt ttcttttagta gattgaattt gttgaccac ttaaaattca	8700
aataccccc attgaacgtg actatgcacca acaatgaaaa atttgacaaa ttgtacattt	8760
gggggggttca ccacccgggt acggacaatg accaaatctt cccgtatgct caagcatcag	8820
gaagaatcac agtctctacc aaaagaagcc aacaaactgt aatcccgaat atcggatcta	8880
gaccgcaggt aaggaatatac cccagcagaa taagcatcta ttggacaata gtaaaaccgg	8940
gagacatact tttgattaac agcacagggg atctaattgc tcttaggggt tacttcaaaa	9000
taacaaatggg gaaaagctca ataatgagat cagatgcacc cattggcaaa tgcaattctg	9060
aatgcacatcac tccaaacggc agcattccca atgacaaacc attccaaat gtaaacaggg	9120
tccacatacgg ggcctgtccc agatatgttta agcaaaacac tctgaaattt gcaacaggg	9180
tgcgaaatgt accagagaaa caaactagag gcataattgg cgcaatcgcc ggtttcatag	9240
aaaatgggttgg ggagggatg gtggatggtt ggtacggttt caggcatcaa aattctgagg	9300
gaataggaca agcagcagat ctcaaaaagca ctcaagcagc aatcgatcaa atcaatggg	9360
agctgaatag gttgatcgaaa aaaaccaacg agaaattcca tcagattgaa aaagaattct	9420
cagaagtcga agggagaatt caggacatttgc agaaatatgt tgaggacacc aaaatagatc	9480
tctggtcata caacgcggag cttcttggcc cctggagaa ccaacataca attgatctaa	9540
ctgactcaga aatgaacaaa ctgtttggaa aaacaaagaa gcaactgagg gaaaatgctg	9600
aggatatggg caatgggtgt ttcaaaatatac accacaaatg tgacaatgcc tgcataggat	9660
caatcagaaa tggaaacttat gaccacgatg tatacagaga tgaagcatta aacaaccgg	9720
tccagatcaa gggcggttagt ctgaagtcag gatacaaaa ttggatccta tggatttcc	9780
ttggccatatac atgttttttgc ctttgggttgc ctttggggg gttcatatcg tggccgtcc	9840
aaaaaggcaa cattaggtgc aacatttgca tttgagttact agaggatcat aatcggccat	9900
accacatttgc tagaggtttt acttgcattt aaaaacctcc cacacccccc cctgaaacctg	9960
aaacataaaaa tgaatgcataat tggatgggtt aacttgcattt ttgcagctta taatggttac	10020
aaataaagca atagcatcac aaatttcaca aataaagcat tttttcact gcattctagt	10080

-continued

```
tgtggtttgt ccaaactcat caatgtatct tatcatgtct ggatctgatc actgcttgag 10140
cctagaagat ccggctgcta acaaagcccg aaaggaagct gagttggctg ctgccaccgc 10200
tgagcaataa ctatcataac ccctaggaga tccgaaccag ataagtgaaa tctagttcca 10260
aactatttg tcattttaa tttcgtatt agcttacgac gctacaccca gttccatct 10320
atttgtcac tcttcctaa ataatccta aaaactccat ttccaccct cccagttccc 10380
aactatttg tccgcccaca gccccggatt ttcttcctg ttatgtttt aatcaaacat 10440
cctgccaact ccatgtgaca aaccgtcatac ttccggctact tt 10482
```

```
<210> SEQ ID NO 2
<211> LENGTH: 8917
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: multi-epitope human papilloma virus-like
particle
```

```
<400> SEQUENCE: 2
ttctctgtca cagaatgaaa attttttgtt catctcttcg ttattaaatgt ttgttaattga 60
ctgaatatac acgttttattt gcagcctgaa tggcgaatgg gacgcgcctt gtatcgccgc 120
attaagcgcg gccccgggtgg tggtaacgccc cagcgtgacc gctacacttg ccagcgcctt 180
agcgcccgct ctttcgtttt tttcccttc ctttctcgcc acgttcgccc gctttccccc 240
tcaagctcta aatcgggggc tccctttagg gttccgattt agtgcatttac ggcaccccg 300
ccccaaaaaa cttgattttagg gtatgggttc acgtatgtgg ccacgcctt gatagacgg 360
ttttcgccct ttgacggtgg agtccacgtt cttatagtg gactcttggt ccaaacttgg 420
acaacactca accctatctc ggtctattttt ttgattttat aaggatggatggatccg 480
gcctatttgtt taaaaatgaa gctgattttaa caaaaatttta acgcgaattttaa taacaaaata 540
ttaacgctta caattttaggtt ggcacttttc gggaaatgtt ggcggaaacc cctattttgtt 600
tattttctta aatacattca aatatgtatcc cgctcatgag acaataaccc tgataaaatgc 660
ttcaataata ttgaaaaagg aagagatgtt gatattcaaca tttccgtgtc gcccattttc 720
cctttttgc ggcattttgc cttcctgtttt ttgctcaccc agaaacgctg gtgaaagttaa 780
aagatgctga agatcagttt ggtgcacgag tgggttacat cgaactggat ctcaacagcg 840
gtaagatcct tgagatgtttt cggcccgaaag aacgttttcc aatgtatgtt acctttaaag 900
ttctgctatgttggcggta ttatcccgtt ttgacgcccgg gcaagagacaa ctccgtcgcc 960
gcatacacta ttctcagaat gacttggttt agtacttacc agtcacagaa aagcatctta 1020
cgatggcat gacagtaaga gaattatgtt gtcgtccat aaccatgtt gataacactg 1080
cgcccaactt acttctgtaca acgtatcgag gaccgaaggg gctaaccgtt tttttgcaca 1140
acatggggga tcatgttaact cgccttgcattt gttggaaacc ggagctgtt gaaagccatac 1200
caaacgacga gcgacgacacc acgtgcctg tagcaatggc aacaacgttgc cgccaaactat 1260
taactggcga actacttactt ctatgtttttt ggcaacaattt aatagactgg atggaggccgg 1320
ataaaagttgc aggaccactt ctgcgtcggtt cccttcggcc tggctggttt attgtgtata 1380
aatctggagc cggtgagcgtt ggggtctcgcc gttatgttgc agcaactgggg ccagatggta 1440
agccctcccg tatactgtttt atctacacgaa cggggagttca ggcaactatg gatgaacgaa 1500
```

-continued

atagacagat	cgctgagata	ggtgccctcac	tgattaagca	ttggtaactg	tcagaccaag	1560
tttactcata	tatactttag	attgatttaa	aacttcattt	ttaatttaaa	aggatctagg	1620
tgaagatcct	ttttgataat	ctcatgacca	aaatcccta	acgtgagttt	tcgttccact	1680
gagcgtcaga	ccccgtagaa	aagatcaaag	gatcttctt	agatcctttt	tttctgcgcg	1740
taatctgctg	cttgcaaaca	aaaaaaccac	cgctaccagc	ggtggttgt	ttgcccggatc	1800
aagagctacc	aactctttt	ccgaaggtaa	ctggcttcag	cagagegcag	ataccaaata	1860
ctgttcttct	agtgttagccg	tagttaggcc	accacttcaa	gaactctgta	gcaccgccta	1920
catacctcgc	tctgctaatac	ctgttaccag	tggctgctgc	cagtggcgat	aagtctgtc	1980
ttaccgggtt	ggactcaaga	cgatagttac	cggataaggc	gcagcggctg	ggctgaacgg	2040
ggggttcgtg	cacacagecc	agcttggagc	gaacgaccta	cacccgactg	agataacctac	2100
agcgtgagct	atgagaaagc	gccacgttcc	ccgaaggggag	aaaggcggac	aggtatccgg	2160
taagcggcag	ggtcggaaca	ggagagegc	cgagggagct	tccaggggg	aacgectgg	2220
atctttatag	tcctgtcggt	tttcgcacc	tctgacttga	gcgtcgattt	ttgtatgt	2280
cgtcaggggg	gccccggccta	tggaaaaacg	ccagcaacgc	ggccctttta	cgggttctgg	2340
cctttgctg	gcctttgtct	cacatgttct	ttcctgcgtt	atccccgtat	tctgtggata	2400
accgttattac	cgccttttag	tgagctgata	ccgctcgccg	cagccgaaac	accgagcgc	2460
gcgagtcagt	gagcgaggaa	gcggaagagc	gcctgatgcg	gtatttctc	cttacgcata	2520
tgtgcggat	ttcacacccgc	atagaccagc	cgcgtaacct	ggcaaaatcg	gttacggtt	2580
agtaataataat	ggatgcctg	cgttaagcggg	tgtggcgga	caataaagtc	ttaaactgaa	2640
caaaatagat	ctaaactatg	acaataaaagt	cttaaactag	acagaatagt	tgtaaactga	2700
aatcagtcca	gttatgctgt	aaaaaagcat	actggactt	tgttatggct	aaagcaaact	2760
cttcattttc	tgaagtgc当地	attgcccgtc	gtattaaaga	ggggcgtggc	caagggcatg	2820
gtaaagacta	tattcgc当地	gttgc当地	tttaccgaac	aactccgc当地	ccgggaagcc	2880
gatctcggt	tgaacgaatt	gttaggtggc	ggtacttgg	tcgatatcaa	agtgc当地	2940
ttcttccgt	atgccc当地	ttgtatagag	agccactgc当地	ggatcgtc当地	cgtaatctc	3000
ttgcacgtag	atcacataag	caccaagc当地	gttggc当地	tgcttgagga	gattgatgag	3060
cgcggc当地	atgc当地	tccggc当地	gccc当地	gctgatgc当地	agatata	3120
ctcaactacgc	ggctgctcaa	acttggc当地	aacgtaagcc	gc当地	caacaaccgc	3180
ttcttggc当地	aaggc当地	gc当地	gttcttacta	c当地	cccgaggt	3240
atcggagtc当地	ggctgatgtt	gggagtaggt	ggctacgtc当地	ccgaaactc当地	gaccgaa	3300
atcaagagca	gccc当地	atttgactt当地	gtcaggcc当地	agcctacatg	tgc当地	3360
gcccaactt	gagccaccta	acttggttt当地	agggc当地	ccctgctgc当地	taacatc当地	3420
gctgctgc当地	aacatcg当地	ctgctccata	acatcaaaca	tc当地	ccccc当地	3480
cttgc当地	ggatgc当地	ggc当地	atagact	gtacaaaaaa	acagtc当地	3540
aaaccgc当地	tgccgc当地	ccaccgc当地	gttgc当地	ggttctggac	c当地	3600
agcgc当地	ctacttgc当地	tacagttt当地	gaaccgaaca	ggctt当地	atctgggtc当地	3660
gtgc当地	ccgttccac	ggtgtgc当地	acccggcaac	cttggc当地	agc当地	3720
aggcatttct	gttctggc当地	gcaacgc当地	gcaaggttc当地	ggctccacg	catcgctagg当地	3780

-continued

cattggcgcc	cttgctgttc	ttctacggca	agggtgtgtg	cacggatctg	cccttgcttc	3840
aggagatcgg	tagacctegg	cegtcgccgg	gcttgcgggt	ggtgtgtacc	ccggatgaag	3900
tggttcgcat	cctcggttt	ctggaaggcg	agcatcgtt	gttcgcccag	gactctagct	3960
atagttctag	tggttggta	cagctttgtt	tgtactatca	acagggttga	ctgctgtatca	4020
acagatcctc	tacgcggccg	cggtaccata	acttcgtata	gcatacatta	tacgaagtt	4080
tctggtttaa	acgtacccgt	agtggctatg	gcagggcttg	ccggcccgac	gttggctgct	4140
agccctgggc	cttcacccga	acttgggggt	tggggtgggg	aaaaggaaga	aacgcgggcg	4200
tattggtccc	aatggggct	cggtggggta	tgcacagagt	gccagccctg	ggaccgaacc	4260
ccgctttat	gaacaaacga	ccaaacaccc	gtgcgtttta	ttctgtcttt	ttattgccgt	4320
catagcgcgg	gttccttccg	gtattgtctc	cttccgtgtt	tcaagttagcc	tccccatct	4380
cccggtaccc	catgctatgc	atatccggg	tgcgtcaagtc	ttcgtcgagt	gattgttaat	4440
aaaatgtaat	ttacagtata	gtatgttaat	taatatacaa	atgatttgc	aataattctt	4500
attnaactat	aatatattgt	gttgggttga	attaaaggc	cgtatactag	tatcgattcg	4560
cggactactc	cggaaatatta	atagatcatg	gagataat	aatgataac	catctcgcaa	4620
ataaataagt	atttactgt	tttcgtaca	gtttgttaat	aaaaaaacct	ataaaatattc	4680
cggattattc	ataccgtccc	accatcgccg	ccggatccgc	caccatgtcc	ctgtggctgc	4740
cctccgaggg	taccgtgtac	ctgccccccg	tgcggcggtc	caagggtgg	tccaccgacg	4800
agtacgtggc	tgcgtaccaac	atctactacc	acgctggcac	ctcccgctctg	ctggctgtgg	4860
gtcaccccta	cttcccccata	aagaagccca	acaacaacaa	gatccgtgt	cccaagggtgt	4920
ccggcctgca	gtaccgtgt	ttccgtatcc	acctgcccga	ccccaaacaag	ttcggtttcc	4980
ccgacacactc	cttctacaac	cctgacaccc	agccgcctcg	gtgggctgtc	gtgggctgtgg	5040
aggtcggccg	tggccagccc	ctgggtgtcg	gtatctccgg	tcacccctcg	ctgaacaagc	5100
tggacgacac	cgagaacgc	tccgcttacg	ctgctaaccgc	tgggtgtcgac	aaccgcgagt	5160
gcacatccat	ggactacaag	cagacccaggc	tgtgcctgt	cggttgc	cccccacatcg	5220
gcgagcactg	gggcagggt	tccccctgca	ccaaacgtggc	tgtgaacccc	ggcgactgcc	5280
ccccctcgca	gctgtatcaac	accgtatcc	aggacggcga	catggtgac	accggtttcg	5340
gtgtatgg	cttcaccacc	ctgcaggctca	acaagtccga	ggtgccccctg	gacatctgca	5400
cctccatctg	caagtaccc	gactacatca	agatgggtgc	cgagccctac	ggcgactccc	5460
tgttcttcta	cctgcgtgt	gagcagatgt	tgcgtgcgtca	cctgttcaac	cgtgtgggt	5520
ctgtggcga	gaacgtgccc	gacgacctgt	acatcaagg	ttccgggtcc	accgctaaacc	5580
tggcttccag	caactacttc	cctacccct	ccgggttccat	ggtcacccctc	gacgctcaga	5640
tcttcaacaa	gccctactgg	ctgcagcggt	ctcagggtca	caacaacgg	atctgtgtgg	5700
gcaaccagct	gttcgtgacc	gtgggtcgaca	ccacccgttc	caccaacatg	tctctgtgcg	5760
ctgtatctc	cacccctcgag	actacactaca	agaacaccaa	cttcaaggag	tacctgcgtc	5820
acggcgagga	gtacgacctg	cagttcatct	tccagctgtg	caagatcacc	ctgaccgctg	5880
acgtgtatgac	ctacatccac	tccatgaact	ccactatcct	cgaagattgg	aacttcggtc	5940
tgcagccccc	tcccggtggc	accctcgagg	acacctaccc	tttcgtcacc	tcccaggct	6000
tcgttgcac	gaagcacacc	ccccctgtatc	ccaaaggagga	ccccctgaa	aagtacaccc	6060

-continued

tctgggaggt caacctgaag gagaagttct ccgctgacct ggaccaggtc cccctgggtc	6120
gcaagttcct gctgcaggcc ggactgaagg ccaagccaa gttcacccctg ggcaagcgca	6180
aggctacccc caccacctcc tccacccctca ccaccgctaa gaggaagaag cgcaagctgt	6240
aaaagcttgt cgagaagttac tagaggatca taatcagccca taccacattt gtagaggttt	6300
tacttgcttt aaaaaacccctc ccacacccctcc ccctgaacct gaaacataaa atgaatgcaa	6360
ttgttggtgt taacttgttt attgcagttt ataatggta caaataaagc aatagcatca	6420
caaatttcac aaataaaagca ttttttcac tgcattctag ttgtggtttgc tccaaactca	6480
tcaatgtatc ttatcatgtc tggatctgtat cactgcttgc gcctagaaga tccggctgt	6540
aacaaagccc gaaaggaagc tgagttggct gctgtggcta gctttgttta actttaagaa	6600
ggagatacat ctgaaatat taatagatca tggagataat taaaatgata accatctcg	6660
aaataaataa gtatttact gttttcgtaa cagttttgtat ataaaaaaaaac ctataaataat	6720
tccggattat tcataccgtc ccaccatcg ggcggatcc gccaccatgg ctctgtggcg	6780
tccctccgac aacaccgtgt acctgcccccc tccctccgtg gctcgtgtgg tcaacaccga	6840
cgactacgtg acccgtaacct ccatcttctca ccacgctgg tccctccgtc tgctgaccgt	6900
ggcaaccccc tacttccgtg tgcccgctgg cggtgccaaac aagcaggaca tccccaaaggt	6960
gtccgcttac cagtaccgtg tggatctgtat gcaatgtgttgc gaccccaaca agttcggtct	7020
gccccacacc tccatctaca accccgagac tcaagccctc gtgtggctt ggcgtgggt	7080
cgagatcggt cgtggccagc ccctgggtgt cggcctgtcc ggtcaccct tctacaacaa	7140
gctggacgac accgagttct cccacgctgc tacctccaaac gtgtccggagg acgtgcgcga	7200
caacgtgtct gtggactaca agcagacccaa gctgtgcata ctgggttgcg ctcccgctat	7260
cggcggacac tgggctaagg gcaccgttgc caagtcccgt cctctgtccc agggcgactg	7320
ccccctctc gagctgaaga acaccgtgtc cgaggacggc gacatggtgg acaccggta	7380
cggtgctatg gacttcagca ccctgcagga caccaagtgc gaggtggcccc tggacatctg	7440
ccagtccatc tgcaagttacc ccgactacccat gcagatgtcc gctgaccct acggcgactc	7500
tatgttcttc tgccctgcgtc gtgagcagct gttcgctcgt cacttctggaa accgtgtctgg	7560
caccatgggt gacaccgtgc cccagtcctc gtacatcaag ggcaccggca tgcgtgttcc	7620
ccccggttcc tgcgtgtact ccccttcccc ctccggttcc atcgtgacct ccgactccca	7680
gctgtcaac aagccctact ggctgcacaa ggctcagggt cacaacaacg gtgtctgt	7740
gcacaaccag ctgttcgtga cctgtggcga caccaccgt tccaccaacc tgaccatctg	7800
cgcttccacc cagtcccccg tgccggccca gtacgacgct accaagttca agcagtaactc	7860
ccgtcacgtg gaggagtaac acctgcgtt cttccatccat ctctgcacta tcaccctgac	7920
cgctgacgtg atgtccatca tccactccat gaactccctt atcctgttgcg attggaaactt	7980
cggtgtcccc cttcccccctt ctacccctt ggtggacact taccgttgcg tgcgtccgt	8040
ggctatcacc tgccagaagg acgctgttcc cgttgagaac aaggaccctt acgacaagct	8100
gaagttctgg aacgtggacc tgaaggagaa gttctccctg gacctggacc agtaccctt	8160
gggtcgcaag ttctctggc aggtggccctt gaggcgcaag cccaccatcg gtcccccggaa	8220
gcgttcccgat ccctccgtat ccacccctcc caagcccgcc aacgtgtgc gtgtgcgcgc	8280
tgcgaagttaa gcttagcaaggc ttgtcgagaa gtactagagg atcataatca gccataaccac	8340

-continued

atttgttagag	gttttacttg	ctttaaaaaa	cctcccacac	ctccccctga	acctgaaaca	8400
taaaatgaat	gcaattgtt	ttgttaactt	gtttattgca	gcttataatg	gttacaata	8460
aagcaatagc	atcacaaattt	tcacaaataa	agcattttt	tcactgcatt	ctagttgtgg	8520
tttgcctaaa	ctcatcaatg	tatcttatac	tgtctggatc	tgatcaactgc	ttgagctag	8580
aagatccggc	tgctaacaaaa	gcccgaagg	aagctgagtt	ggctgctgcc	accgctgagc	8640
aataactatc	ataaccctta	ggagatccga	accagataag	tgaaatctag	ttccaaacta	8700
ttttgtcatt	ttaattttc	gtattagctt	acgacgctac	acccagttcc	catctat	8760
gtcaacttcc	cctaaataat	ccttaaaaac	tccatttca	cccctccag	ttcccaacta	8820
ttttgtccgc	ccacagcggg	gcattttct	tcctgttatg	tttttaatca	aacatctgc	8880
caactccatg	tgacaaaaccg	tcatcttcgg	ctacttt			8917

<210> SEQ ID NO 3
 <211> LENGTH: 10595
 <212> TYPE: DNA
 <213> ORGANISM: Artificial
 <220> FEATURE:
 <223> OTHER INFORMATION: multi-epitope influenza B virus-like particle

<400> SEQUENCE: 3

ttctctgtca	cagaatgaaa	attttctgt	catctcttcg	ttattaatgt	ttgttaattga	60
ctgaatatac	acgcttattt	gcagcctgaa	tggcgaatgg	gacgcgcct	gtageggcgc	120
attaagcgcg	gcgggtgtgg	tggttacgcg	cagcgtgacc	gctacacttg	ccagcgcct	180
agcgcgcgt	ccttcgcgtt	tcttcccttc	ctttctcgcc	acgttcgcgc	gtttccccc	240
tcaagctcta	aatcgggggc	tccctttagg	gttccgattt	agtgcattac	ggcacctcga	300
ccccaaaaaa	cttgatttagg	gtgatggttc	acgtagtggg	ccatcgccct	gatagacgg	360
ttttgcctt	ttgacgttgg	agtccacgtt	cttaatagtg	gactcttgg	ccaaactgga	420
acaacactca	accctatctc	ggtctattct	tttgattttat	aaggatttt	gcccatttcg	480
gcctattgg	taaaaaatga	gctgatttaa	aaaaattta	acgcgaattt	taacaaaata	540
ttaacgctta	caattttagt	ggcacttttc	ggggaaatgt	gcfgcgaacc	cctatttgg	600
tattttcta	aatacattca	aatatgtatc	cgctcatgag	acaataaccc	tgataaaatgc	660
ttcaataata	ttgaaaaagg	aagagtatga	gtattcaaca	tttccgtgtc	gcccttattc	720
cctttttgc	ggcattttgc	cttcctgttt	ttgctcaccc	agaaacgctg	gtgaaagtaa	780
aagatgctga	agatcagttg	ggtgcacgag	ttggttacat	cgaactggat	ctcaacagcg	840
gtaagatcct	tgagagttt	cgccccgaag	aacgtttcc	aatgtatgagc	acttttaaag	900
ttctgctatg	tggcgccgta	ttatcccgt	ttgacgcccgg	gcaagagcaa	ctcggtcgcc	960
gcatacacta	ttctcagaat	gacttggttg	agtactcacc	agtcacagaa	aagcatctta	1020
cggatggcat	gacagtaaga	gaattatgca	gtgctgcct	aaccatgagt	gataacactg	1080
cggccaactt	acttctgaca	acgatcggag	gaccgaagga	gctaaccgct	ttttgcaca	1140
acatggggga	tcatgtact	cgccttgc	gttgggaacc	ggagctgaat	gaagccatac	1200
caaacgacga	gcgtgacacc	acgatgcctg	tagcaatggc	aacaacgttg	cgcaaactat	1260
taactggcga	actacttact	ctagcttccc	ggcaacaatt	aatagactgg	atggaggcgg	1320
ataaaagttgc	aggaccactt	ctgcgcctgg	cccttcggc	tggctggttt	attgctgata	1380

-continued

aatctggagc	cggtgagcgt	gggtctcgcg	gtatcattgc	agcaactgggg	ccagatggta	1440
agccctcccg	tatcgttagtt	atctacacga	cgggggagtca	ggcaactatg	gatgaacgaa	1500
atagacagat	cgcgtgagata	ggtgcctcac	tgattaagca	ttggtaactg	tcagaccaag	1560
tttactcata	tatactttag	attgatttaa	aacttcattt	ttaatttaaa	aggatctagg	1620
tgaagatcct	ttttgataat	ctcatgacca	aaatccctta	acgtgagttt	tcgttccact	1680
gagcgtcaga	ccccgtagaa	aagatcaaag	gatcttcttg	agatcctttt	tttctgcgcg	1740
taatctgctg	cttgcaaaca	aaaaaaccac	cgctaccagc	ggtggtttg	ttgccggatc	1800
aagagctacc	aactctttt	ccgaaggtaa	ctggcttcag	cagagegcag	ataccaaata	1860
ctgttcttct	agtgtagecg	tagttaggccc	accacttcaa	gaactctgta	gcacccgcta	1920
catacctcgc	tctgctaatac	ctgttaccag	tggctgctgc	cagtggcgat	aagtcgtgtc	1980
ttaccgggtt	ggactcaaga	cgatagttac	cgagataaggc	gcagcggtcg	ggctgaacgg	2040
ggggttcgtg	cacacageccc	agcttggagc	gaacgaccta	cacccgactg	agataacctac	2100
agcgtgagct	atgagaaagc	gccacgcttc	ccgaagggag	aaaggcggac	aggtatccgg	2160
taagcggcag	ggtcggaaca	ggagagcgca	cgagggagct	tccaggggg	aacgccttgt	2220
atctttatag	tcctgtcggg	tttcgcacc	tctgacttga	gcgtcgattt	ttgtgtatgct	2280
cgtcaggggg	gcccggccta	tggaaaaacg	ccagcaacgc	ggccctttta	cggttccctgg	2340
cctttgctg	gcctttgtt	cacatgttct	ttcctgcgtt	atccctgtat	tctgtggata	2400
accgttattac	cgcctttgag	tgagctgata	ccgctcgccg	cagccgaac	accgagcgc	2460
gcgagtca	gagcggaggaa	gcggaagagc	gcctgtatgcg	gtatcttc	cttacgcata	2520
tgtgcggat	ttcacaccgc	atagaccagc	cgcgtaacct	ggcaaaatcg	gttacggtt	2580
agtaataaaat	ggatgcctg	cgtaagcggg	tgtggggcga	caataaagtc	ttaaactgaa	2640
caaaatagat	ctaaactatg	acaataaaagt	cttaaactag	acagaatagt	tgtaaactga	2700
aatcagtcca	gttatgctgt	aaaaaagcat	actggactt	tgttatggct	aaagcaaact	2760
cttcattttc	tgaagtgcaa	attgcccgtc	gtattaaaga	ggggcgtggc	caagggcatg	2820
gtaaagacta	tattcgcggc	gttgtgacaa	tttaccgaac	aactccgcgg	ccgggaagcc	2880
gatctcggt	tgaacgaatt	gttaggtggc	ggtacttggg	tcgatataca	agtgcatac	2940
ttcttcccg	atgccaact	ttgtatagag	agccactgcg	ggatcgtac	cgtaatctgc	3000
ttgcacgtag	atcacataag	caccaagcgc	gttggcctca	tgcttgagga	gattgatgag	3060
cgcggtggca	atgcccgtcc	tccgggtc	gcccggagact	gcgagatcat	agatataagat	3120
ctcaactacgc	ggctgctcaa	acttggcag	aacgttaagcc	gcgagagcgc	caacaaccgc	3180
ttcttggcgt	aaggcagca	gcgcgtatgaa	tgtcttacta	cgcgagcaat	tcccgaggta	3240
atcggagtc	ggctgatgtt	gggagtaggt	ggctacgtct	ccgaactcac	gaccgaaaag	3300
atcaagagca	gccccatgg	atttgacttg	gtcaggcccg	agcctacatg	tgcgaatgat	3360
gccataactt	gagccaccta	actttgtttt	agggcgactg	ccctgctgcg	taacatcggt	3420
gctgctgcgt	aacatcggt	ctgctccata	acatcaaaca	tcgacccacg	gcgttaacgcg	3480
cttgctgctt	ggatgcccga	ggcatagact	gtacaaaaaa	acagtctataa	caagccatga	3540
aaaccggccac	tgcggcgta	ccaccgcgtc	gttcggcataa	ggttctggac	cagttgcgtg	3600
agcgcatacg	ctacttgcat	tacagtttac	gaaccgaaca	ggcttatgtc	aactgggttc	3660

-continued

gtgccttcat	ccgtttccac	ggtgtgegtc	accggcaac	cttgggcagc	agcgaagtgc	3720
aggcatttct	gttctggctg	gsgaacgagc	gcaaggttc	ggtctccacg	catcgtagg	3780
cattggcgcc	cttgctgttc	ttctacggca	agggtgtgt	cacggatctg	cccttgcttc	3840
aggagatcgg	tagacctegg	cggtcggggc	gcttgcgggt	ggtgctgacc	ccggatgaag	3900
tggttcgcat	cctcggtttt	cttggaaaggcg	agcatcggtt	gttcggccag	gactctagct	3960
atagttctag	tgggtggcta	cagctttgtt	tgtactatca	acagggttga	ctgctgatca	4020
acagatcctc	taegcggccg	cggtaccata	acttcgtata	gcatacatta	tacgaagtt	4080
tctgggttaa	acgttacccgt	agtggctatg	gcagggcttg	ccggcccgac	gttggctgct	4140
agccctgggc	cttcacccga	acttgggggt	tgggggtgggg	aaaaggaaga	aacggggcg	4200
tattggtccc	aatggggct	cggtggggta	tgcacagagt	gccagccctg	ggaccgaacc	4260
ccgcgtttat	gaacaaacga	cccaacaccc	gtgcgtttta	ttctgtcttt	ttattggcg	4320
catagcgcgg	gttccttccg	gtattgtctc	cttccgtgtt	tcaagtttgc	tcccccattct	4380
cccggtacct	tataagtatt	tcctcacaag	agctgaattt	cccatagagc	tctgttttag	4440
cactccatt	acatctttgg	caattccttc	tccattctt	tgacttgctc	ctagagatct	4500
caacactcca	atgttggttt	gcagcttcc	tgcttagttt	tggacgttct	ctcccttcc	4560
cattccatc	attgttcttg	ctgtgttcat	agctgaaacc	atctgcattt	ctcggtttac	4620
tccaggtacc	gaagaccttg	ctgctctgct	atgggctcta	tgcgagtgcg	atgcttgg	4680
ctcgcataaa	gcacagagcg	ttccttagttt	tacttgcatt	aatagttttt	cagggtttag	4740
gtacatgacc	ataagacaat	atagtaatgc	tgagcttgc	tggccttctg	ctatttcaaa	4800
tgcttcatga	aagcttacac	atcttctcat	ttttctctca	gctagaatta	ggccttctt	4860
ctttgttgc	gttggccc	ttcctgacag	gggctctgt	atgaatctcc	ttttttttcc	4920
ttggcttttg	ggttttaaaa	agcatataga	ggcaccaatt	agtgtttttt	gtatatacgt	4980
taggcacctt	ttgtttttta	tccattccaa	agcagaatct	aggtcaaatt	ctttccacc	5040
gaaccaacag	tgtatatttt	cagcttagttc	tgctttgcct	tctccatctt	ctatttagtga	5100
aagcaggtag	gcaattgtgt	ctccaaacag	cgacatgggt	gcatccccgg	tgtcaagtc	5160
ttcgtcgagt	gattgttaat	aaaatgtaat	ttacagtata	gtattttaat	taatatacaa	5220
atgatttgc	aataatttctt	atthaactat	aatatattgt	gttgggttga	ataaaaggct	5280
cgtatactag	tatcgattcg	cgacctactc	cgaaatattta	atagatcatg	gagataattt	5340
aaatgataac	catctcgaa	ataaataatgt	attttactgt	tttcgttaaca	gttttgcata	5400
aaaaaaaccc	ataaaatattc	cggttatttc	ataccgtccc	accatcgccc	gcggatccac	5460
catgaaggca	ataattgtac	tactcatgt	gttcaaaaaca	gccactcaag	gggaggtcaa	5520
tggaaataaca	tcttcaaact	cacctcatgt	gttcaaaaaca	gccactcaag	gggaggtcaa	5580
tgtgactgg	gtgataccac	taacaacaac	accaacaaaa	tcttattttg	caaatactcaa	5640
aggaacaagg	accagaggga	aactatgcc	agactgtctc	aactgcacag	atctggatgt	5700
ggcttgggc	agaccaatgt	gtgtggggac	cacacccctcg	gcttggggac	caataactcc	5760
cgaagtcaaa	cctgttacat	ccgggtgttt	tcctataatg	cacgacagaa	caaaaatcag	5820
gcaactaccc	aatcttctca	gaggatgtga	aaatatcagg	ctatcaaccc	aaaacgtcat	5880
cgatgcggaa	aaggcaccag	gaggacccta	cagacttgga	acctcaggat	cttgcctcaa	5940

-continued

cgctaccagt aagagcggat tttcgcaac aatggcttg gctgtccaa aggacaaca	6000
caaaaatgca acgaacccac taacagttaga agtaccatac atttgtacag aaggggaaga	6060
ccaaatcaact gttgggggt tccattcaga tgacaaaacc caaatgaaga acctctatgg	6120
agactcaaata cctcaaaagt tcacctcatc tgctaattgga gtaaccacac actatgttc	6180
tcagattggc agcttcccag atcaaacaga agacggagga ctaccacaaa gcggcaggat	6240
tgttggatgat tacatgatgc aaaaacattgg gaaaacagga acaattgtct accaaagagg	6300
tgtttgttg cctcaaaagg tgtggcgcg gagtggcagg agcaaaagtaa taaaagggtc	6360
cttgccctta attgggtgaag cagattgcct tcatgaaaaa tacggtgat taaacaaaag	6420
caaggcattac tacacaggag aacatgcaaa agccatagga aattgccaa tatgggtgaa	6480
aacacctttg aagcttgcata atgaaaccaa atatagacct cctgcaaaac tattaaagga	6540
aaggggtttc ttccggagcta ttgctgggtt cctagaagga ggatggaaag gaatgattgc	6600
aggctggcact ggatacacat ctcacggagc acatggagtg gcagtggcgg cggacctaa	6660
gagtacgcaa gaagctataa acaagataac aaaaaatctc aattcttga gtgagctaga	6720
agtaaaagaat cttcaaaagac taagtggatgc catggatgaa ctccacaacg aaatactcga	6780
gctggatgag aaagtggatg atctcagagc tgacactata agctcgcata tagaacttgc	6840
agtcttgcctt cccaacgaa gaataataaa cagtgaagat gagcatctat tggcacttga	6900
gagaaaacta aagaaaatgc tgggtccctc tgctgttagag ataggaaatg gatgcttcga	6960
aaccaaacac aagtgcacacc agacctgctt agacaggata gctgctggca ccttaatgc	7020
aggagaattt tctctccca cttttgattc actgaacatt actgctgcat cttaaatga	7080
tgatggattt gataaccata ctatactgcctt ctattactca actgctgctt ctagttggc	7140
tgtaacattt atgcttagcta tttttattttt ttatatggtc tccagagaca acgtttcatg	7200
ctccatctgt ctataagtgc acgtactaga ggatcataat cagccataacc acatttttag	7260
aggttttact tgctttaaaaa aacctccac acctcccccgaacctgaaa cataaaatga	7320
atgcaattttt tggtttaac ttgtttattttt cagttataa tggttacaaa taaagaataa	7380
gcatcacaaa tttcacaaat aaagcattttt tttcactgca ttctagttgtt ggtttgtcca	7440
aactcatcaa tttatcttcat catgtctggc tctgatcaact gcttgagctt agaagatccg	7500
gctgctaaca aagcccgaaa ggaagctgag ttggctgtg tggctagttt tgtttaactt	7560
taagaaggag atacatctag aaatattaaat agatcatgga gataattaaa atgataacca	7620
tctcgcaaat aaataagtat tttactgtttt tcgttaacagt tttgtataaa aaaaacctat	7680
aaatattccg gattattcat accgtcccac catcgccgcg ggatccacca tgctaccc	7740
aactatacaa acgttaaccc tatttctcac atcaggggga gtgttattt cactatatgt	7800
gtcagcttca ttgtcataact tactatattt ggatataatggctt cttttttttt cacaacaga	7860
aataactgca ccaataatgc cattggattt tgcaaaacgca tcaaatgttc aggctgtgaa	7920
ccgttctgca gcaaaagggg tgacacttctt tttccagaa ccggagtgga cataccctcg	7980
tttatcttgc ccgggctcaa cttttcagaa agcacttcaattttagggccccc atagattcg	8040
agaaaacccaa gggaaactcag ctcccttgcata aataaggaa ctttttatttgc ttgtggacc	8100
aacggaaatgc aaacacttttgc ctctaaacccaa ttatgcagctt caaccagggg gataactacaa	8160
tggaaacaaga gaagacagaa acaagctgag gcatctaaat tcaatgtttttt tggcaaaaat	8220

-continued

cccaacagta gaaaactcca tttccatat ggcagcttgg agcgggtccg catgecatga	8280
tggtaaagaa tggacatata tggagttga tggcccccac agtaatgcata tactaaaaat	8340
aaaatatggaa gaagcatata ctgacacata ccattctat gcaaaaaaca tcctaaggac	8400
acaagaaagt gcctgcaatt gcatcgaaaa agattgttat cttatgataa ctgatggccc	8460
agcttcaggg attagtgaat gcagattcct taagattcga gagggccgaa taataaaaga	8520
aatatccaa acagaaagag taaaacatac tgaggaatgc acatcgccat ttgcacgcaa	8580
caaaaccata gaatgtgctt gtagagataa cagttacaca gcaaaaagac cctttgtcaa	8640
attnaatgtg gagactgataa cagcggaaaat aagattgtatg tgacacagaga cttatttggaa	8700
caccccccaga ccaaattgtatg gaagcataac agggccttgc gaatctgtatg gggacaaagg	8760
gagtgaggc atcaagggag gatttgcata tcaaagaatgc gcatccaaatg ttggaaagggt	8820
gtactctcga acgtatgtata aaactaaaag aatggggatg ggactgtatg taaagtatga	8880
tggagaccca tggactgaca gtgaageccct tgctcttagt ggagtaatgg ttgcgtatgg	8940
agaacctgggtt tggatttgcata aataaaagat aagaaatgtg atgtccctgt	9000
tattggata gaaatggatc atgatgggtt gaaaacgact tggcactcag cagcaacagc	9060
catttactgt ttaatgggtt caggacaact gctgtggac actgtcacag gtgttgcata	9120
ggctctgtaa atcgatgaca agcttgcata gaaatgtatc aggtatcataa tcagccatac	9180
cacatttgcata gagggtttac ttgcattttaa aaccccccac caccccccac tgaacccgt	9240
acataaaatg aatgcatttgcata ttgttgcata cttgtttattt gcaatgtatc atggttacaa	9300
ataaaagcaat agcatcacaat atttcacaaa taaagcattt ttttgcatac attctatgtt	9360
tggtttgcata aactatgtatc atgtatgtatc tcatgtatgg atctgtatc tgcttgcata	9420
tagaagatcc ggctgtatc aacggccgaa aggaagctga gttggctgtatc gggtgcataa	9480
tgagtgagct aactcacatt aattggccgg aatattataa gatcatggatc ataattaaaa	9540
tgataaccat ctcgcaataa aataatgtt ttactgtttt cgtaacatgtt ttgtatggaa	9600
aaaacccata aatattccgg attattcata ccgtcccccac atcggccgcg gatccaccat	9660
gctcgaacca tttcagatcc tttcaattttt ttcttttgcata ttcgcatac tccatttgcata	9720
ggcttggaca atagggcatt tgaatcaat aaaaagagga ataaacatgc aaatacgaat	9780
aaaagggtcca aacaagaga caataaaacag agaggtatca attttgcatac acagttacca	9840
aaaagaaatc caggccaaag aaacaatgaa ggaagttactc tctgacaaca tggaggttt	9900
gagtgaccac ataataatttgcata aggggcttc tgccgaaagag ataataaaaaa tgggtgaaac	9960
agttttggag atagaagaat tgcattttgcata actagaggat cataatcagc cataccacat	10020
ttgttagaggt ttactttgcata taaaatggatc tcccacatcc cccccctgcata ctgaaacata	10080
aaatgtatc aattttttgcata ttattttgcata tttttttgcata tttttttgcata tttttttgcata	10140
gcaatagcat cacaatgtatc acaaaatggatc cttttttgcata actgcatttc agttttttgcata	10200
tgtccaaacttgcata tttttttgcata tttttttgcata tttttttgcata tttttttgcata tttttttgcata	10260
gatccggctg ctaacaaacgc ccgaaaggaa gctgagttgg ctgctgcac ccgtgacaa	10320
taactatcat aaccccttgcata agatccgcata cagataatgtt aatctatgtt ccaaaatgtt	10380
ttgtcattttt taaaatgtatc attagttttgcata gacgtttttgcata ccgtttttgcata tttttttgcata	10440
cactcttccca taaataatcc taaaatgtatc cttttttgcata cccatccatcc tttttttgcata	10500

-continued

ttgtccggcc acagcggggc attttcttc ctgttatgtt ttaatcaaa catcctgcca	10560
actccatgtg acaaaccgtc atcttcggct acttt	10595
<210> SEQ ID NO 4	
<211> LENGTH: 8411	
<212> TYPE: DNA	
<213> ORGANISM: Artificial	
<220> FEATURE:	
<223> OTHER INFORMATION: multi-epitope papilloma virus-like particle	
<400> SEQUENCE: 4	
ttctctgtca cagaatgaaa attttctgt catctttcg ttattaatgt ttgttaattga	60
ctgaatatca acgcttattt gcagcctgaa tggcgaatgg gacgcgcct gtageggcgc	120
attaagcgcg gcgggtgtgg tggtaegcg cagcgtgacc gctacacttg ccagegcct	180
agcgcccgct ctttcgttt ctttcccttc ctttctcgcc acgttcgcgg gctttcccg	240
tcaagctcta aatcgggggc tccctttagg gttccgattt agtgctttac ggcaacctcg	300
ccccaaaaaa cttgatttagg gtgatggttc acgttagtggg ccatcgccct gatagacggt	360
ttttcgccct ttgacgttgg agtccacgtt cttaatagtg gactcttggt ccaaacttgg	420
acaacactca accctatctc ggtctattct tttgatttt aagggatttt gccgatttcg	480
gcctattggtaaaaaatga gctgatttaa caaaaattha acgcgaattt taacaaaata	540
ttaacgctta caatttaggt ggcacttttc gggaaatgt gcgcgaaacc cctatttgg	600
tattttctta aatacattca aatatgtatc cgctcatgag acaataaccc tgataaatgc	660
ttcaataata ttgaaaaagg aagagtagtga gtattcaaca tttccgtgtc gcccattttc	720
cctttttgc ggcattttgc cttcctgttt ttgctcaccc agaaacgctg gtgaaagtaa	780
aagatgctga agatcagttt ggtgcacgag tgggttacat cgaactggat ctcaacagcg	840
gtaagatcct tgagagttt cgccccgaag aacgttttc aatgtatgagc acttttaag	900
ttctgctatg tggcgcggta ttatcccgtt ttgacgcggg gcaagagcaa ctgggtcgcc	960
gcatacacta ttctcagaat gacttgggtt agtactcacc agtcacagaa aagcatctta	1020
cggatggcat gacagtaaga gaattatgca gtgctgccc aaccatgagt gataacactg	1080
cggccaactt acttctgaca acgatcggag gaccgaagga gctaaccgct ttttgacaca	1140
acatggggga tcatgtact cgccttgcgtt gttggaaacc ggagctgaat gaagccatac	1200
caaacgacga gcgtgacacc acgatgcctg tagcaatggc aacaacgttg cgcaaactat	1260
taactggcga actacttaact ctatgttccc ggcaacaatt aatagactgg atggaggcgg	1320
ataaaagttgc aggaccactt ctgcgcgtgg cccttccggc tggctggttt attgctgata	1380
aatctggagc cggtgagcgt gggtctcgcg gtatcattgc agcactgggg ccagatggta	1440
agccctcccg tatactgtttt atctacacga cggggagtc ggcacactatg gatgaacgaa	1500
atagacagat cgctgagata ggtgcctcac tgatatttttgc ttggtaactg tcagaccaag	1560
tttactcata tatacttttag attgatttaa aacttcattt ttaattaaa aggatctagg	1620
tgaagatcct ttttgcataat ctcatgcacca aaatccctta acgtgagttt tcgttccact	1680
gagcgtcaga ccccgtagaa aagatcaaag gatcttcttg agatcctttt tttctgcgcg	1740
taatctgctg cttgcaccaaaaaccac cgctaccagc ggtggtttgc ttgcggatc	1800
aagagctacc aactctttt ccgaaggtaa ctggcttcag cagagcgcag ataccaaata	1860

-continued

ctgttcttct agtgtagecg tagttaggcc accacttcaa gaactctgta gcacccgcta	1920
catacctcgc tctgctaatac ctgttaccag tggctgctgc cagtggcgat aagtctgtc	1980
ttaccgggtt ggactcaaga cgatagttac cggataaggc gcagcggctg ggctgaacgg	2040
ggggttcgtg cacacagecc agcttggagc gaacgaccta caccgaactg agataacctac	2100
agcgtgagct atgagaaagc gccacgcttc ccgaagggag aaaggcggac aggtatccgg	2160
taagcggcag ggtcggaaca ggagagcgca cgagggagct tccaggggaa aacgcctgg	2220
atctttatag tcctgtcggt ttcgcacc tctgacttga gcgtcgattt ttgtatgct	2280
cgtcaggggg gcggagccctt tggaaaaacg ccagcaacgc ggcctttta cggttctgg	2340
cctttgctg gcctttgtt cacaatgttct ttcttgcgtt atccctgtat tctgtggata	2400
accgttattac cgcctttgag tgagctgata cgcgtcgccg cagccgaacg accgagcgca	2460
gcgagtcaatg gagcgaggaa gggaaagagc gcgtgtatgcg gtatgttctt cttacgcatt	2520
tgtgcggat ttcacacccgc atagaccagc cgcgtaacct ggcaaaatcg gttacggttt	2580
agtaataat ggtatgcctg cgtaageggg tgggggggaa caataaagtc tttaactgaa	2640
caaaaatagat ctaaaactatg acaataaaatg cttaaactatg acagaatagt tgtaaaactgaa	2700
aatcagtcca gttatgtgtt gaaaaagcat actggactt ttttatggctt aaagcaaaact	2760
cttcatttttca tgaagtgcattt attgcccgtc gtattaaaga ggggcgtggc caaggccatg	2820
gttaaagacta tattcgcggc gttgtgacaa ttaccgaac aactccgcgg ccggaaagcc	2880
gatctcggtt tgaacgaatt gtttaggtggc ggtacttggg tcgatataca agtgcatac	2940
ttcttccgtt atgcccactt ttgtatagag agccactgcg ggatcgatc acgtatctgc	3000
ttgcacgtat atcacataag caccaagcgcc gttggccctca tgcttgaggaa gattgtatgag	3060
cgcgggtggca atgcccctgc tccgggtctc gcccggagact gcgagatcat agatataat	3120
ctcaactacgc ggctgctcaa acttggggcg aacgtaaagcc gcgagagcgca caacaaccgc	3180
ttcttgggtcg aaggcagca ggcgtatgaa tgcgttacta cggagcaatg tcccgaggta	3240
atcgaggatcc ggctgtatgtt gggagtaggtt ggctacgtct cggactacatc gaccgaaaag	3300
atcaagagca gcccgcattt atttgacttgc gtcaggcccg agcctacatg tgcaatgtat	3360
gccctactt gagccaccta actttgtttt agggcgactg ccctgctgcg taacatcgat	3420
gctgtcgctt aacatcgatgctt ctgtccata acatcaaaaca tcgacccacg ggcgtacgc	3480
cttgcgtctt ggatgcccga ggcgtatgact gtacaaaaaa acgtatcaaa caagccatgaa	3540
aaaccggccac tgcgcgttta ccaccgtgc gttcggtcaa gggtctggac cagttcggtt	3600
agcgcatacg ctacttgcatt tacatgtttac gaaccgaaca ggcttgcgtt aactgggttc	3660
gtgccttcat cgcgttccac ggtgtgcgtc accccggcaac cttggcccg agcgtatgtc	3720
aggcatttttctt gtcgttgcgtt ggcgtatgact gcaagggtttc ggtctccacg cttcgatgtt	3780
cattggccgc cttgcgtgtt tcctacggca aggtgtgttgc cacggatctg ccctgtttt	3840
aggagatcggtt tagacctcggtt ccgtcgccggc gttgcgggtt ggtgtatgacc ccggatgaa	3900
tggttcgat cctcggtttt ctggaaaggccg agcatcgatg ttgcggccatg gactctgtat	3960
atagttctatg tgggtggatc cagttttgtt tgactatca acagggttcaa ctgtatgtatca	4020
acagatcctc tacgcggcccg cggatccata acttcgtata gcatacattttt tacgaatgtt	4080
tctggtttaa acgttacccgtt agtggctatg gcaagggtttt cggccccgac gttggatgtcg	4140

-continued

agccctggc	cttcacccga	acttgggggt	tgggtgggg	aaaaggaaga	aacggggcg	4200
tattggccc	aatggggtct	cggtggggta	tgcacagagt	gccageccctg	ggacgaaacc	4260
cgggtttat	gaacaaacga	cccaacaccc	gtgcgttta	ttctgtctt	ttattggcgt	4320
catagcgcgg	gttccttcgg	gtattgtctc	cttccgtgtt	tcagttagcc	tcccccacatct	4380
cccggtaccc	catgctatgc	ataagcttt	acagcttgcg	cttcttcctc	ttagegggtgg	4440
tggaggtgga	ggaggtgggt	ggggtagcct	tgcgcttgc	cagggtgaac	ttgggtttgg	4500
ctttcagttcc	ggcctgcagc	aggaacttgc	gaccagggg	gaactggtcc	aggtagcg	4560
agaacttctc	cttcagggtt	accccaga	aggtgtactt	cttcaggggg	tcctccttgg	4620
gagcagggggg	ggtgtgttcc	tggcaagcga	tagcctggga	ggtgaegaaa	cggtaggtgt	4680
cctcgggggt	gccaccggga	gggggctgca	gaccgaagtt	ccaatcttcg	aggatagtgg	4740
agttcatgga	gtggatgttag	gtcatcacgt	cagcggtcag	ggtgatcttgc	cacagcttgg	4800
agatgaactg	caggtcgtac	tcctcgeccgt	gacgcaggtt	ctccttgaag	ttgggtttct	4860
tgttaggtgt	ctcggagggt	gagatagcag	cgcacagaga	catgttggtgg	gaacgggtgg	4920
tgtcgaccac	ggtcacgaa	agctgggtgc	cccagcagat	accgttgg	tgacccttag	4980
cacgctgcag	ccagtagggc	ttgttgaaga	tctgagcgtc	ggaggtgacc	atggAACCGG	5040
agggggtagg	gaagtaggttgc	cttggaaagcga	ggtttagcgtt	ggaaaccggaa	cccttgcgtgt	5100
acaggtcg	gggcacgttc	tcgcccacag	caccagcacg	gttgaacagg	tgacgcacga	5160
acatctgctc	acgacgcagg	tagaagaaca	gggagtcgc	gtagggctcg	gacaccatct	5220
tgtatgtatgc	ggggtagttgc	catatggagg	tgcagatgtc	caggggcacc	tcggacttgc	5280
tagcctgcag	ggtgtgtgaag	tccatagcac	cgaaaccgggt	gtccaccatg	tcggccgtcct	5340
ggatcacgg	gttgatcgc	tcgagagggg	ggcagtcgc	ggggttcaca	gccacgttgg	5400
tgcaggggga	acccttgc	cagtgc	cgatgggggg	cttgc	accgc	5460
gctgggtctg	cttgcgttgc	atggagatgc	actcgcgtt	gtcgacacca	gcgttagcag	5520
cgtaaagcgg	agcgttctcg	gtgtcg	cttgcgttgc	cagggttgc	ccggagatac	5580
cgacacccag	gggctggcca	cggccgac	ccacgcccac	gcaagcccac	acgaggcg	5640
gggtgtcagg	gttgtagaag	gagggtgc	ggaaaccggaa	cttgcgttgc	tcgggcaggt	5700
ggatacggaa	cacacggta	tgcaggccgg	acaccttgc	caccaggatc	ttgttgcgt	5760
tgggcttctt	gatggggaa	taggggtgac	ccacagccag	cagacgggag	gtgccacgt	5820
ggtagtagat	gttggtacga	gccacgtact	cgtcggttgc	caccaccc	gacacggc	5880
cggggggcag	gtacacggta	gcctcg	ggacccacag	ggacatgg	gcggatccat	5940
ccgggtgtat	caagtctcg	tcgagtgatt	gtaaataaaa	tgtattac	agtatagat	6000
ttaattaaat	atacaaatga	tttgataata	attcttattt	aactataata	tattgtttgc	6060
ggttgaatta	aaggccgt	tactgtatc	gattcg	ctactccgg	atattaatag	6120
atcatggaga	taattaaat	gataaccatc	tcgcaaaataa	ataagtattt	tactgtttc	6180
gtaacagttt	tgtaataaaa	aaacccatataa	atattccgg	ttattcatac	cgtcccacca	6240
tggggccgg	atccgc	accatggctgt	ggcgtccctc	cgacaacacc	gtgtac	6300
ccctccctc	cgtggctgt	gtggtaaca	ccgacgacta	cgtgacc	cgttac	6360
tctaccacgc	tggttctcc	cgtctgt	ccgtggccaa	ccctacttc	cgtgtcccc	6420

-continued

ctggcggtgg	caacaageag	gacatccccca	aggtgtccgc	ttaccagtagc	cgtgtttcc	6480
gtgtgcagct	gccccgacccc	aacaagttcg	gtctgcccga	cacctccatc	tacaaccccg	6540
agactcagcg	cctcgtgtgg	gcttgcgtcg	gtgtcgagat	cggtcgtggc	cagccccctgg	6600
gtgtcgccct	gtccggteac	cccttctaca	acaagctgga	cgacaccggag	tcctccacg	6660
ctgtctaccc	caacgtgtcc	gaggacgtgc	gcgacaacgt	gtctgtggac	tacaaggcaga	6720
cccgagctgt	catactgggt	tgcgctcccg	ctatcgccga	gcactgggct	aagggcacccg	6780
cttgcaagtc	ccgtcctctg	tcccaggggcg	actgcccccc	tctcgagctg	aagaacacccg	6840
tgctcgagga	cggcgacatg	gtggacacccg	gttacgggtc	tatggacttc	agcacccctgc	6900
aggacaccaa	gtgcgagggtg	cccctggaca	tctgccagtc	catctgaaag	taccccgact	6960
acctgcagat	gtccgctgac	ccctacggcg	actctatgtt	cttctgctct	cgtcgtagc	7020
agctgttgc	tcgtcacttc	tggAACCGT	ctggcaccat	gggtgacacc	gtgccccagt	7080
ccctgtacat	caagggcacc	ggcatgegtg	cttccccccg	ttcctgcgtg	tactccctt	7140
ccccctccgg	ttccatcggt	acctccgact	ccagctgtt	caacaagccc	tactggctgc	7200
acaaggctca	gggtcacaac	aacgggtct	gtggcacaa	ccagctttc	gtgaccgtgg	7260
tcgacaccac	ccgttccacc	aacctgacca	tctgcgttc	cacccagtcc	cccggtcccc	7320
gccagtagca	cgctaccaag	ttcaaggcgt	actcccgta	cgtggaggag	tacgacactgc	7380
agttcatctt	ccagctctgc	actatcaccc	tgaccgctga	cgtgatgtcc	tacatccact	7440
ccatgaactc	ctctatcttc	gaagattgga	acttcggtgt	ccccctcccc	cccactacct	7500
ccctgggtgga	cacttacgt	ttcgtgcagt	ccgtggctat	cacctgcccag	aaggacgctg	7560
ctcccgctga	gaacaaggac	ccctacgaca	agctgaagtt	ctggaacgtg	gacctgaagg	7620
agaagttctc	cctggacctg	gaccagtacc	ccctgggtcg	caagttcctg	gtgcaggctg	7680
gcctgaggcg	caagcccacc	atcggtcccc	gcaagcgttc	cgctccctcc	gctaccaccc	7740
cctccaagcc	cggcaagcgt	gtgcgtgtgc	gcgctcgcaa	gtaagctagc	aagcttgc	7800
agaagtagtacta	gaggatcata	atcagccata	ccacattttgt	agaggttta	cttgctttaa	7860
aaaacctccc	acacctcccc	ctgaacctga	aacataaaat	gaatgcaatt	gttgttgc	7920
acttgcgttat	tgcagcttat	aatggttaca	aataaagcaa	tagcatcaca	aatttcacaa	7980
ataaaagcatt	tttttcactg	cattcttagt	gtggttttgc	caaactcatac	aatgtatctt	8040
atcatgtctg	gatctgatca	ctgcttgagc	ctagaagatc	cggctgctaa	caaagcccga	8100
aaggaagctg	agttggctgc	tgccaccgct	gagcaataac	tatcataacc	ccttaggagat	8160
ccgaaccaga	taagtgaaat	ctagttccaa	actatTTTGT	catttttaat	tttcgttatta	8220
gcttacgacg	ctacacccag	ttcccatcta	ttttgtca	cttccctaaa	taatccctaa	8280
aaactccatt	tccacccctc	ccagttccca	actatTTTGT	ccgcccacag	cggggcattt	8340
ttttccctgt	tatgtttta	atcaaacatc	ctgccaactc	catgtgacaa	accgtcatct	8400
tcggctactt	t					8411

<210> SEQ ID NO 5
<211> LENGTH: 8445
<212> TYPE: DNA
<213> ORGANISM: Artificial
<220> FEATURE:
<223> OTHER INFORMATION: multi-epitope papilloma virus-like particle

-continued

<400> SEQUENCE: 5

ttctctgtca	cagaatgaaa	atttttctgt	catctcttcg	ttattaatgt	ttgttaattga	60
ctgaatatca	acgcttattt	gcagccctgaa	tggcgaatgg	gacgcgcct	gtageggcgc	120
attaaggcgg	gcgggtgtgg	tggtaacgcg	cagcgtgacc	gctacacttg	ccageggcct	180
agcgcggcgt	ccttcgttt	tttcccttc	ctttctcgcc	acgttcgccc	gctttccccg	240
tcaagctcta	aatcgggggc	tccctttagg	gttccgattt	agtgccttac	ggcacctcga	300
ccccaaaaaa	cttgatttagg	gtgatggttc	acgttagtggg	ccatcgccct	gatagacggt	360
ttttcgccct	ttgacgttgg	agtccacgtt	cttaatagtg	gactcttggt	ccaaactggaa	420
acaacactca	accctatctc	ggtctattct	tttgatttat	aaggattttt	gccgatttcg	480
gcctattggt	taaaaaatga	gtgatttaa	aaaaattta	acgcgaattt	taacaaaata	540
ttaacgctta	caattttaggt	ggcacttttc	ggggaaatgt	gchgccaacc	cctatttggt	600
tattnnctca	aatacattca	aatatgtatc	cgctcatgag	acaataaccc	tgataaaatgc	660
ttcaataata	ttgaaaaagg	aagagtatga	gtattcaaca	tttccgtgtc	gcccttattc	720
cctttttgc	ggcattttgc	cttcctgttt	ttgctcaccc	agaaacgctg	gtgaaagtaa	780
aagatgctga	agatcagttg	ggtgacacgag	tgggttacat	cgaactggat	ctcaacagcg	840
gtaagatcct	tgagagttt	cggcccaagaa	aacgttttcc	aatgatgagc	acttttaaag	900
ttctgctatg	tgccgcggta	ttatcccgta	ttgacgcccgg	gcaagagcaa	ctcggtcgcc	960
gcatacacta	ttctcagaat	gacttggttt	agtactcacc	agtcacagaa	aagcatctta	1020
cggtatggcat	gacagtaaga	gaattatgc	gtgctgccc	aaccatgagt	gataacactg	1080
cggccaaactt	acttctgaca	acgatcggag	gaccgaagga	gctaaccgct	tttttgcaca	1140
acatggggga	tcatgttaact	cgccttgatc	gttgggaacc	ggagctgaat	gaagccatac	1200
caaacgacga	gcgtgacacc	acgatgcctg	tagcaatggc	aacaacgtt	cgcaaactat	1260
taactggcga	actacttaact	ctagcttccc	ggcaacaatt	aatagactgg	atggaggccgg	1320
ataaagttgc	aggaccactt	ctgcgctcg	cccttccggc	tggctggttt	attgctgata	1380
aatctggagc	cggtgagcgt	gggtctcg	gtatcattgc	agcactgggg	ccagatggta	1440
agccctcccg	tatcgtagtt	atctacacga	cggggagtca	ggcaactatg	gatgaacgaa	1500
ataagacagat	cgctgagata	gggtgcctac	tgatthaagca	ttggtaactg	tcagaccaag	1560
tttactcata	tatacttttag	attgatttaa	aacttcattt	ttaatttaaa	aggatctagg	1620
tgaagatcct	ttttgataat	ctcatgacca	aaatccctta	acgttagttt	tcgttccact	1680
gagcgtcaga	ccccgtagaa	aagatcaaag	gatcttctt	agatcctttt	tttctgcgcg	1740
taatctgctg	cttgcaaaca	aaaaaaaccac	cgctaccagc	ggtggtttgt	ttgcccggatc	1800
aagagctacc	aactctttt	ccgaaggtaa	ctggcttcag	cagagcgcag	ataccaaata	1860
ctgttcttct	agtgttagccg	tagtttagcc	accacttcaa	gaactctgt	gcaccgccta	1920
cataacctcg	tctgctaatac	ctgttaccag	tggctgctgc	cagtggcgat	aagtctgtgc	1980
ttaccgggtt	ggactcaaga	cgatagttac	cgataggc	gcagcggcgc	ggctgaacgg	2040
gggggtcg	cacacagccc	agcttggagc	gaacgaccta	caccgaactg	agataactac	2100
agcgtgagct	atgagaaagc	gccacgttcc	ccgaaggag	aaaggcggac	aggtatccgg	2160
taagcggcag	ggtcggaaca	ggagagcgca	cgagggagct	tccaggggaa	aacgcctggt	2220

-continued

atctttatag	tcctgtcgaa	tttcgcacc	tctgacttga	gcgtcgattt	ttgtgtatgt	2280
cgtcaggggg	gcggagccaa	tggaaaaaac	ccagcaacgc	ggccctttta	cggttcttgg	2340
ccttttgcgt	gcctttgt	cacatgttct	ttccctgtgtt	atccctgtat	tctgtggata	2400
accgttattac	cgcctttgag	ttagctgata	ccgctcgccg	cagccgaacg	accgagcgc	2460
gcgagtcagt	gagcgaggaa	gcggaagagc	gcctgtatgcg	gtatttctc	cttacgcac	2520
tgtgcggat	ttcacacccgc	atagaccagc	cgctgtatgcg	gtatccatgt	tttacgggtt	2580
agtaataaat	ggatgcctg	cgtaagcggg	tgtgggggaa	caataaagt	ttaaaactgaa	2640
caaaatagat	ctaaactatg	acaataaaatg	cttaaaactatg	acagaatagt	tgtaaactgaa	2700
aatcagtcca	gttatgtgt	gaaaaagcat	actggacttt	tgttatggct	aaagcaaact	2760
cttcattttc	tgaagtgc	attgcgcgtc	gtatccatgt	ggggcgtggc	caagggcat	2820
gtaaagacta	tattcgcggc	gttgcgaa	tttaccgaa	aactccgg	ccggaaagcc	2880
gatctcggt	tgaacgaatt	gttaggtggc	ggtacttgg	tgcataatca	agtgcac	2940
ttcttccgt	atgcaccaact	ttgtatagag	agccactgcg	ggatcgtc	atctgc	3000
ttgcacgtag	atcacataag	caccaagcgc	gttgcgtca	tgcttgagg	gattgtatgag	3060
cgcgggtggca	atgcacccgtc	tccgggtgtc	gcggagact	gcgagatcat	agatataat	3120
ctcaactacgc	ggctgtctaa	acttgggca	aacgtaa	gcgagagcgc	caacaaccgc	3180
ttcttgggt	aaggcagcaa	gcgcgatgaa	tgtcttacta	cgaggca	gttccggat	3240
atcggagtc	ggctgtatgtt	gggagtaggt	ggctacgtct	ccgaactc	gaccgaaaag	3300
atcaagagca	gcggccatgg	atttgcgtt	gtcaggccgc	agcctacat	tgcgtatgt	3360
gcccatactt	gagccacca	actttgtttt	agggcgact	ccctgtcg	taacatcg	3420
gctgtcggt	aacatcg	ctgtccata	acatcaaaca	tgcacccac	gcgtac	3480
cttgcgtgtt	ggatgcgc	ggcatagact	gtacaaaaaa	acagtctata	caagccat	3540
aaaccggccac	tgcgcgtt	ccaccgcgtc	gttgcgtt	ggttctgg	cagttgcgt	3600
agcgcatacg	ctacttgc	tacatgttac	gaaccgaa	ggcttgcgt	aactgggtt	3660
gtgccttc	ccgtttccac	gggtgtcg	acccggca	cttgggc	agcgtatgt	3720
aggcatttct	gttgcgtgt	gcgtacgac	gcaagggtt	ggtctccac	catcg	3780
cattggcg	cttgcgtgtt	ttctacggca	agggtgtgt	cacggatgt	ccctgtgtt	3840
aggagatcg	tagacctcg	ccgtcgccgc	gcttgcgtt	ggtgctgacc	ccggatgaa	3900
tggttcgat	cctcggttt	ctggaaaggc	agcatcg	gttgcgtt	gactctatgt	3960
atagttctat	tgggtggata	cagtttgtt	tgtactatca	acagggtt	atgcgtat	4020
acagatcc	tacgcggcc	cggtaccata	acttcgtat	gcatacatt	tacgaaat	4080
tctggttcg	acctactcc	gaatattaa	agatcatg	gataattaa	atgataac	4140
tctcgcaat	aaataatgt	tttactgttt	tgcgtat	tttgcataaa	aaaaacat	4200
aaatattcc	gattattat	accgtcccac	catcgccgc	ggatccgca	ccatgtcc	4260
gtggctgccc	tccgaggc	ccgtgtac	gcggccgt	cccggt	gttcc	4320
cacccgac	tacgtggc	gtaccaacat	ctactaccac	gctggcac	cccggt	4380
ggctgtgggt	cacccctact	tcccccata	gaagccaa	aacaacaaga	tcctgg	4440
caaggtgtcc	ggcgtgc	actgtgtt	ccgtatccac	ctggccgacc	ccaacaat	4500

-continued

cggttcccc gacacctct tctacaaccc tgacacccag cgccctcggt gggcttgcgt	4560
ggcgtggag gtcggccgtg gccagccccc ggggtgtcggt atctccggtc acccccgtct	4620
gaacaagctg gacgacaccc agaacgcgttc cgcttaagct gctaacgctg gtgtcgacaa	4680
ccgaggtgc atctccatgg actacaagca gacccagctg tgcctgtatcg gttcaagcc	4740
ccccatcgcc gaggactggg gcaagggttc cccctgcacc aacgtggctg tgaacccgg	4800
cgactgcccc cctctcgagc tgcatacac acgtgatccag gacggcgaca tgggtggacac	4860
cggttcggt gctatggact tcaccaccc gcaggctaac aagtccgagg tgcccctgga	4920
catctgcacc tccatctgca agtaccccgta ctacatcaag atggtgtccg agccctacgg	4980
cgactccctg ttcttctacc tgcgtcgta gcagatgttc gtgcgtcacc tggtaaccg	5040
tgctgggtgt gtgggcgaga acgtgccccg acgtgatccatcaac aagtccgagg tgcccctgga	5100
cgctaaccctg gttccagca actactccc tacccctcc ggttccatgg tcaccccgaa	5160
cgctcagatc ttcaacaagc cctactggct gcagcggtct cagggtcaca acaacggat	5220
ctgctggggc aaccagctgt tgcgtgacccgt ggtcgacacc acccgttcca ccaacatgtc	5280
tctgtgcgtct gctatctcca cctccgagac tacctacaag aacaccaact tcaaggagta	5340
cctgcgtcac ggcgaggagt acgacactgca gttcatcttc cagctgtgca agatcaccct	5400
gaccgctgac gtgtgacccat acatccactc catgaactcc actatccctg aagattggaa	5460
cttcggctcg cagccccctc ccgggtggcac cctcgaggac acctaccgtt tcgtcacctc	5520
ccaggctatc gttgccaga agcacaccccc ccctgctccc aaggaggacc ccctgaagaa	5580
gtacacccctc tgggagggtca acctgaagga gaagttctcc gctgacccgtt accagttccc	5640
cctgggtcgc aagttcctgc tgcaggccgg actgaaggcc aagcccaagt tcacccctgg	5700
caagcgcaga gctaccccca ccacccctcc cacctccacc accgctaaga ggaagaagcg	5760
caagctgtaa aagcttgcg agaagacta gaggatcata atcagccata ccacattgt	5820
agaggtttta ctgcgtttaa aaaacctccc acacctcccc ctgaacctga aacataaaat	5880
gaatgcaatt gttgtgtta acttgcgtt atgcgttata aatggttaca aataaagcaa	5940
tagcatcaca aatttcacaa ataaaggattt ttttcactg cattctagtt gtggttgtc	6000
caaactcatac aatgtatctt atcatgtctg gatctgtatca ctgcgtgagc ctgcgtatc	6060
cggctgctaa caaagccccgaa aaggaagctg agttggctgc tggctgcgttcc tttgtttaac	6120
ttaagaagg agatacatct agaaatattta atagatcatg gagataatta aaatgataac	6180
catctcgcaa ataaataatgt attttactgt ttgcgtaaacat gttttgtat aaaaaaacct	6240
ataaaatattc cggattattc ataccgtccc accatcgggc gggatccgc caccatggct	6300
ctgtggcgctc cctccgacaa caccgtgtac ctgcctccccc cctccgtggc tcgtgtggc	6360
aacaccgacg actacgtgac ccgtacccctcc atcttctacc acgctgggttcc tccctgtctg	6420
ctgaccgtgg gcaaccccta cttccgtgtg cccgctggcg gtggcaacaa gcaggacatc	6480
cccaagggtgt ccgttacca gtaccgtgtg ttccgtgtgc agctgccccgaa ccccaacaaag	6540
ttcggctcgcc ccgacacccctc catctacaac cccgagactc agcgccctcggttgc	6600
gctgggtgtcg agatcggtcg tggccagccccc ctgggtgtcg gctgtccgg tcaccccttc	6660
tacaacaagc tggacgacac cggatccctcc caccgtgtacat cctccaaacgt gtccgaggac	6720
gtgcgcgaca acgtgtctgt ggactacaag cagacccaggc tgcgtatccctt ggggttgcgt	6780

-continued

cccgctatcg	gcgagcaactg	ggctaagggc	accgcttgca	agtcccgtcc	tctgtccccag	6840
ggcgactgcc	ccccctctega	gctgaagaac	accgtgctcg	aggacggcga	catgggtggac	6900
accgggttacg	gtgctatgga	cttcagcacc	ctgcaggaca	ccaaagtgcga	ggtgcctcgt	6960
gacatctgcc	agtccatctg	caagtacccc	gactacctgc	agatgtccgc	tgaceccctac	7020
ggcgactcta	tgttcttctg	cctgcgtcg	gagcagctgt	tcgctcgta	cttctggAAC	7080
cgtgctggca	ccatgggtga	caccgtgcc	cagtcctgt	acatcaaggg	caccggcatg	7140
cgtgcttccc	ccgggttcctg	cgtgtactcc	ccttccccct	ccgggttccat	cgtgacccctcc	7200
gactccccc	tgttcaacaa	gcctactgg	ctgcacaagg	ctcagggtca	caacaacgggt	7260
gtctgctggc	acaaccagct	gttcgtgacc	gtggtcgaca	ccaccggttc	caccaacactg	7320
acatctctcg	cttccaccca	gtcccccgtg	ccggccca	acgacgctac	caagttcaag	7380
cagtaactccc	gtcacgtgga	ggagtagcgc	ctgcagttca	tcttcctag	ctgcactatc	7440
acccctgaccc	ctgacgtgt	gtcctacatc	cactccatga	actcccttat	cctcgaagat	7500
tggaaactcg	gtgtcccccc	tcccccact	accccccctgg	tggacactta	ccgttctgt	7560
cagtcctgtgg	ctatcacctg	ccagaaggac	gctgctcccg	ctgagaacaa	ggacccttac	7620
gacaagctga	agttctggaa	cgtggacctg	aaggagaagt	tctccctgg	cctggaccag	7680
tacccctgg	gtcgcaagtt	cctgggtcg	gctggctga	ggcgcaagcc	caccatcggt	7740
ccccgcaagc	gttccgcctcc	ctccgcctacc	acccctccca	agcccgccaa	gcgtgtgcgt	7800
gtgcgcgc	gcaagtaagc	tagcaagctt	gtcgagaagt	actagaggat	cataatcagc	7860
cataccacat	ttgttagaggt	tttacttgct	ttaaaaaacc	tcccacacct	ccccctgaac	7920
ctgaaacata	aatgaatgc	aattgttgt	gttaacttgt	ttattgcagc	ttataatgg	7980
tacaataaaa	gcaatagcat	cacaaatttc	acaaataaag	catttttcc	actgcattct	8040
agttgtggtt	tgtccaaact	catcaatgt	tcttatcatg	tctggatctg	atcactgtt	8100
gagcctagaa	gatccggctg	ctaacaaagc	ccgaaaggaa	gctgagttgg	ctgctgccac	8160
cgctgagcaa	taactatcat	aacccctagg	agatccgaac	cagataagtg	aaatctagtt	8220
ccaaactatt	ttgtcatttt	taattttcg	attagttac	gacgctacac	ccagttccca	8280
tctatTTTGT	cactcttccc	taaataatcc	ttaaaaactc	cattccacc	cctccagtt	8340
cccaactatt	ttgtccgccc	acagcggggc	atttttctc	ctgttatgtt	tttaatcaaa	8400
catcctgcca	actccatgtg	acaaaccgtc	atcttcggct	acttt		8445

1. A recombinant virus-like particle comprising two or more different epitopes or different proteins comprising epitopes which are selected either (a) from different viral strains of the same virus and/or (b) from different serotypes of the same virus and/or (c) from different viral strains specific for different hosts.

2. The recombinant virus-like particle according to claim 1 comprising three or more different epitopes or different proteins comprising epitopes.

3. The recombinant virus-like particle according to claim 1 comprising four or more different epitopes or different proteins comprising epitopes.

4. The recombinant virus-like particle according to claim 1 comprising six, nine or twelve epitopes or different proteins comprising epitopes.

5. The recombinant virus-like particle according to claim 1 wherein the epitopes are from three or more different virus strains or serotypes.

6. The recombinant virus-like particle according to claim 1 further comprising B- and/or T-cell epitopes.

7. The recombinant virus-like particle according to claim 1 further comprising proteins forming a complete virus-like surface and optionally capsid and/or nucleopore proteins.

8. The recombinant virus-like particle according to claim 1 further comprising fluorescent proteins, proteins useful for purification purposes of the particles or for attaching a label, and/or proteinaceous structures required for transport processes.

9. The recombinant virus-like particle according to claim 1 wherein the virus is influenza virus.

10. The recombinant virus-like particle according to claim **1** wherein the virus is human papilloma virus.

11. A vector comprising two or more polynucleotides coding for different epitopes or for different proteins comprising epitopes which are selected either (a) from different viral strains of the same virus and/or (b) from different serotypes of the same virus and/or (c) from different viral strains specific for different hosts.

12. The vector according to claim **11** encoding a recombinant virus-like particle comprising two or more different epitopes or different proteins comprising epitopes which are selected either (a) from different viral strains of the same

virus and/or (b) from different serotypes of the same virus and/or (c) from different viral strains specific for different hosts.

13. The vector according to claim **11** which is a baculoviral vector.

14. The vector according to claim **11** comprising a polynucleotide sequence selected from SEQ ID NO: 1 to 5.

15. A host cell comprising a vector according to claim **11**.

16. A vaccine comprising a recombinant virus-like particle according claim **1**.

* * * * *